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Abstract 
Vascular calcification occurs during physiological aging and is clinically recognized as a 
major risk factor for myocardial infarction, systolic hypertension, heart failure and 
coronary insufficiency caused by loss of aortic recoil.  Medial arterial calcification is an 
active remodeling process that involves the deposition of bone-specific matrix in close 
association with elastic fibers.  Elastin, a major structural protein in the extracellular 
matrix of arterial walls, provides elastic recoil to the arteries.  Increasing evidence 
suggests that vascular calcification share features with skeletal bone formation such as 
bone matrix deposition and bone resorption.  Bone morphogenetic proteins and bone cells 
have been found in explanted atherosclerotic plaques.  In bone, a homeostasis is 
maintained by its two major cell types; osteoblasts and osteoclasts.  Osteoblasts form new 
bone matrix and osteoclasts, multinucleated giant cells which are derived from bone 
marrow progenitor cells, are responsible for bone resorption. 
Osteoclasts are derived from the monocyte/macrophage lineage of bone marrow 
progenitor cells.  Bone marrow progenitor cells differentiate into osteoclasts by cytokines 
released by neighboring cells like activated T-lymphocytes, osteoblasts or bone marrow 
stromal cells.  Receptor activator of nuclear factor-kB ligand (RANKL) and 1α, 
25(OH)2D3 (Vitamin D3) are examples of stimulates for osteoclast activation.   
The objective of this project was to evaluate the use of osteoclasts differentiated from 
bone marrow progenitor cells as a cell therapy to treat vascular elastin-specific 
calcification.
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Chapter One 
Introduction 
According to the Centers for Disease Control, vascular disease is the leading cause of 
death in the United States accounting for about 27% of deaths [1]. In many vascular 
pathologies vascular calcification is observed. Arterial calcification leads to a hardening 
of the artery and a narrowing of the lumen which affects blood flow.  Vascular 
calcification was once considered an end-stage passive crystallization process in which 
mineral precipitates in extracellular fluids saturated with calcium and phosphates [2]-4].  
However, studies over last 10 years have firmly established that arterial calcification is an 
active regulated process similar to physiologic bone mineralization and associated with 
the presence of bone growth factors and matrix proteins [3-4]. Elastin, a major structural 
protein in the extracellular matrix of arterial walls, provides elastic recoil to the arteries. 
Vascular calcification occurs in two distinct regions. Intimal atherosclerotic calcification 
associated with plaques and medial elastin and vascular smooth muscle cells 
calcification.  Bone morphogenetic proteins and bone cells have been found in explanted 
atherosclerotic plaques as well as in medial arterial calcification in close association with 
elastic fibers.  In bone, a homeostasis is maintained by its two major cell types; 
osteoblasts and osteoclasts.  Osteoblasts form new bone matrix and osteoclasts, 
multinucleated giant cells which are derived from bone marrow progenitor cells, are 
responsible for bone resorption. Bone marrow progenitor cells differentiate into 
osteoclasts by cytokines released by neighboring cells like activated T-lymphocytes, 
osteoblasts or bone marrow stromal cells.  Receptor activator of nuclear factor-kB ligand 
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(RANKL) [3] and 1α, 25(OH)2D3 (Vitamin D3) are examples of cells that stimulate 
osteoclast activation.  Osteoclasts have unique ability to resorb hydroxyapatite. As 
vascular calcification resembles bone formation with active osteoblastic cells, the 
objective of this project was to evaluate the use of osteoclasts differentiated from bone 
marrow progenitor cells as a cell therapy to resorb vascular calcification. 
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Chapter Two 
Literature Review 
According to the Centers for Disease Control, vascular disease is the leading cause of death in the 
United States accounting for about 27% of deaths.  Vascular disease has been the leading cause of 
death for more than 20 years [1].  Arterial calcification leads to a hardening of the artery and a 
narrowing of the lumen which affects blood flow.  Vascular calcification was once considered an 
end-stage passive crystallization process in which mineral precipitates in extracellular fluids 
saturated with calcium and phosphates [2],[4],[5].  Recent findings have shown arterial 
calcification to be a more active regulated process associated with the presence of bone growth 
factors and matrix proteins [5] [4].  Osteoclasts are the only one cell type capable of resorbing 
bone.  This review will outline the mechanisms of vascular calcification, how it resembles bone 
and how bone resorbing cells may be the key to reversing vascular calcification. 
Outline 
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1. Normal Arterial Structure and Composition 
The human vascular system is made up of several different arteries and veins.  Native arteries are 
comprised of a network of three distinct layers.  Each layer has a distinct function and cells that 
help facilitate in that.  The artery also has several extra cellular matrix components that provide 
strength and elasticity to the artery.  Arteries can be categorized into to two major types.   
1.1 Two Types of Arteries 
There are two main types of arteries in the human body.  The type of artery depends on its size 
and function.  The two types of arteries are elastic and muscular.  They are very similar and have 
one main distinguishing factor, the amount of elastin in the artery. 
1.1.1 Elastic 
Larger arteries that conduct blood from the heart are elastic arteries with a diameter around 2.5 
centimeters.  The aorta and its main branches like the carotid, subclavian and iliac arteries are 
examples of these types of arteries.  The arteries stretch in response to bolus of blood and 
passively contract to regulate blood pressure.  Elastic arteries are known for their multilayered 
internal and external elastic lamellae surrounding the tunica media which protects the artery from 
bursting during expansion and contraction. Elastic arteries have a media comprised of 40-70 
elastic lamellae and very rich in smooth muscle cells and collagen. 
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Figure 1.  Diagram of an elastic artery. 
(http://www.srmcheart.com/images/cvprofile%20.jpg ) 
 
1.1.2 Muscular 
Muscular arteries are considered distributing arteries because they distribute blood to the body.  
These arteries are smaller than elastic arteries and have a diameter ranging from 0.3 to 1.0 
millimeters. The intimal layer is very similar in both elastic and muscular arteries, but they have 
very different tunica media layers.  The tunica media of muscular arteries has 3-40 smooth 
muscle cell layers that dominate the elastic lamellae.  The flow of blood is adjusted in these 
arteries by the smooth muscle cell layers of the tunica media which respond to sympathetic nerve 
stimulation.   
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Figure 2.  Diagram of a muscular artery. 
(http://www.sci.sdsu.edu/class/bio590/pictures/lect5/artery-vein.jpeg) 
 
 
1.2 Layers of the Artery 
Native arteries are comprised of three main layers:  tunica intima, tunica media and tunica 
adventitia.  Each layer has a different function and is made of different cells.  The thickness of the 
tunica layer increases as it gets farther from the blood stream. 
1.2.1 Tunica Intima 
The tunica intima is the innermost layer of the artery that actually comes in contact with the 
blood.  This layer consists of a layer of single endothelial cells and a very thin basal membrane of 
connective tissue.  The basal membrane serves to anchor the endothelial cells and provide 
selective movement of nutrients to tissue.   
1.2.2 Tunica Media 
The tunica media layer is surrounded by the internal and external elastic lamellae. The internal 
elastic lamellae separate the intima and media while the external lamellae divide the media and 
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adventitia.  The tunica media is composed of smooth muscle cells embedded in a network of 
collagen and elastin.  The smooth muscle cells in the media of elastic arteries are oriented 
circumferentially into concentric layers separated by elastin sheets.   
 1.2.3 Tunica Adventitia 
The tunica adventitia is the strong outermost covering of arteries.  This layer consists of fibroblast 
cells in a matrix of mostly collagen.  The matrix of the tunica media contains sympathetic nerves 
which regulate expansion and contraction of the arteries.  This layer also contains a vaso vasorum 
which is a network of vessels to provide nutrients to the outer layer of the artery which lacks 
nutrient support from the intimal layer.   
1.3 Cells of the Artery 
The three most prominent cells in the artery are endothelial, smooth muscle and fibroblast cells.  
Each cell is localized to a different layer of the artery and has its distinct role.  Although each cell 
has its own function, they all affect the other cells in the artery. 
1.3.1 Endothelial Cells 
Endothelial cells are arranged in a monolayer and line the lumen of all blood and lymphatic 
vessels.  These cells have a flat morphology and in culture are arranged in a cobblestone pattern, 
but a spindle shape when exposed to flow and they align parallel to direction of shear flow.  
Endothelial cells synthesize a protein-polysaccharide layer which attaches to the basement 
membrane of the arteries known as the endothelium.  The endothelium seals the vessel, but does 
allow limited fluid transport.  It also prevents blood from sticking to the luminal wall. 
 
Endothelial cells also regulate the coagulation of blood by controlling circulating levels of 
thrombin.  Other functions of endothelial cells are to regulate platelet activity, fibrin recruitment 
and vasodilatory responses.  Depending on the circumstances endothelial cells can prevent or 
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encourage platelet activity by secreting anti-platelet factors like nitric oxide and prostacyclin or 
pro-platelet factors like von-willebrand factor.  Fibrin clots are broken down by the secretion of 
fibrinolysis by endothelial cells.  These cells also regulate the action of smooth muscle cells by 
producing vasodilators such as nitric oxide, prostacyclin and endothelin.   
1.3.2 Smooth Muscle Cells 
Smooth muscle cells (SMCs) are 30-40 microns long with fusiform or spindle-shaped 
morphology.  SMCs contain a single nucleus, mitochondria and thick and thin filaments like 
myosin and actin.  SMCs are organized in bundles which are oriented circumferentially and 
surrounded by elastic fibers especially in elastic arteries.  These cells are interconnected by gap 
junctions which are specialized ports between cells that allow ion transport.  Vascular SMCs 
function in contraction and relaxation of arteries, synthesis and secretion of matrix, lipid 
regulation and proliferation for repair and injury. 
1.3.3 Fibroblasts 
Fibroblasts in the tunica adventitia function in normal remodeling of the connective tissue.  
Fibroblasts are contained in the adventitia and remain un-activated until an injury occurs.  In 
response to injury fibroblasts migrate to the neointima and secrete cytokines for vascular 
remodeling [6-8]. 
1.4 Matrix Components of the Artery 
The extracellular matrix (ECM) of arteries consists of a network of collagen, elastin, 
proteoglycans and glycosaminoglycans in order of abundance.  These matrix components give the 
artery strength and support [9].   
1.4.1 Collagen 
Collagen is the most abundant protein in arteries by weight [10].  This protein is very stable and 
has a very low turnover rate.  The prominent types of collagen found in vasculature are collagen 
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types I and III which form fibers by lateral aggregation and undergo lysyl oxidase-mediated 
crosslinking.  Collagen types IV and V are found in the basement membrane of arteries [11].  
Type IV has great flexibility provided by helical interruptions while type V is associated with 
types I and III and regulates collagen fiber formation giving tensile strength to the connective 
tissue of the basement membrane.  Collagen type VI is a microfibrillar collagen distributed only 
in the aorta.   
1.4.2 Elastin 
Elastin is the extracellular matrix protein responsible for the elasticity of skin, arteries and lung 
[12, 13].  Elastic fibers are assemblies that provide certain tissues with resilience, permitting 
long-range deformability and passive recoil without energy input [14].  Many tissues require 
elasticity for physiologic function [15].  Elastin fibers are present in the medial layer of the aorta 
and elastic arteries in concentric fenestrated lamellae separated by smooth muscle cell layers [14].  
These elastic fibers allow the vessels to maintain blood pressure by expansion during systole and 
recoil during diastole [15]. 
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Figure 3. Cross-section of an artery showing orientation of elastin. 
(Adapted from http://www.nature.com/nature/journal/v420/n6917/images/nature01323-
f4.0.jpg) 
 
Elastin is an insoluble, hydrophobic and extensively cross-linked protein [12, 16].  It is 
synthesized only by embryonic, rapidly growing tissues and cells derived from them [15].  Elastin 
has a very low turnover in the body with a half-life of 70 years or more and can undergo 2 billion 
stretch/relaxation cycles in the aortic arch during its lifetime [16].  Elastic fibers are designed to 
function for a lifetime, but a few enzymes mainly matrix metalloproteinases and serine proteases 
are able to cleave elastic fiber molecules [14].  Due to its low turnover rate, degradation of elastin 
fibers leads to a number of diseases in the lungs and arteries.  Destruction of lung elastin caused 
by excessive elastase activity leads to emphysema [17].  Studies have shown one of the causes of 
Marfan‟s syndrome to be a mutation in the elastin synthesis gene [18].   
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Tropoelastin is the precursor to elastin.  Tropoelastin is secreted into the extracellular space of 
tissue and through the activity of the copper-requiring enzyme lysyl oxidase it becomes highly 
crosslinked [15].  Elastin is constituted of polypeptide chains of tropoelastin monomers joined 
together by cross-links called desomosine [12, 19].  The high degree of cross-linking of 
tropoelastin, which takes place in the extracellular space is crucial for proper function of the 
elastic fiber [15].  A critical step in the cross-linking pathway is the formation of a bifunctional 
lysine cross-link intermediate, which then condenses with another bifunctional intermediate on a 
second chain to form the tetrafunctional desmosine cross-links, which are exclusive to elastin [15] 
[20].   
 
 
 
Figure 4.  Elastin structure in a relaxed and stretched state.  Elastin molecules and 
desmosine crosslinks are shown in stretched state.  [21] 
 
1.4.3 Other Components 
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Glycosaminoglycans (GAGs) are amorphorus ground substance found in the ECM of vasculature.  
It is made of unbranched long-chain polymers of repeating disaccharide units.  GAGs are highly 
negatively charged and hydrophilic because of the normally sulfated sugar residue of the 
repeating disaccharide.  Examples of GAGs are hyaluronic acid (which is the only non-sulfated 
GAG), chondroitin sulfate, dermatan sulfate, heparin sulfate, heparin and keratin sulfate. GAGs 
play an important role in tissue hydration by pulling large amounts of water into the ECM.  They 
are also involved in different roles in vasculature.  For example, heparin is a potent anticoagulant 
and others like heparin sulfate, dermatan sulfate and heparin bind to low and very low-density 
lipoproteins and possibly affect plaque formation.  GAGs are covalently bound to protein in the 
form of proteoglycans.  Proteoglycans contain a protein core with 50 or more attached GAG 
chains.  Proteoglycans are localized to the basement membrane of arteries and have a high 
turnover rate [11].  
 
Other components of the ECM of arteries which are found in lower abundance are fibronectin and 
laminin [11].  Both are glycoproteins but laminin is localized to the basement membrane and 
specifically attaches to endothelial cells and collagen type IV.  Fibronectin is found in both tissue 
and blood in a soluble form.  In blood is participates in the wound healing cascade and promotes 
platelet adhesion.  In tissues it controls cell motility and differentiation.   
 
2. Vascular Calcification 
Vascular calcification was once considered an end-stage passive crystallization process in which 
mineral precipitates in extracellular fluids saturated with calcium and phosphates [2, 4, 5, 22].  
Arterial calcification leads to a hardening of the artery and a narrowing of the lumen which 
affects blood flow.  Recent findings have shown arterial calcification to be a more active 
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regulated process associated with expression of growth factors, matrix proteins and bone-related 
proteins [4, 5, 23].  There are two distinct types of arterial calcification:  intimal calcification and 
medial calcification.  
2.1 Intimal Calcification 
Intimal calcification is calcification associated with atherosclerotic plaque [24].  High cholesterol, 
high blood pressure and smoking are all causes of atherosclerosis [25].  It occurs almost 
exclusively in the intimal layer of the artery and is associated with lipid deposition, macrophage 
accumulation and activation of  vascular smooth muscle cells [26].  Intimal calcification is 
hypothesized to begin with an injury to the intimal layer.  An abundance of lipoproteins in the 
blood stream can cause endothelial cell dysfunction.  The lipoproteins can then migrate through 
the intimal layer and causing an inflammatory response after becoming oxidized.  This 
inflammatory response induces an infiltration of macrophages to the sub-endothelial space which 
absorb oxidized lipids and become foam cells forming a lipid core which hardens into a fibrous 
plaque that can grow to impede the flow of blood through the intima.  It can grow to the point of 
total obstruction or break away to cause more damage upstream or possibly myocardial infarction 
or stroke. 
15 
 
 
Figure 5.  Intimal calcification with advanced atherosclerotic plaque. 
(http://www.nmh.org/nmh/adam/adamencyclopedia/graphics/images/en/18018.jpg) 
 
2.1.1 Treatment Options 
As atherosclerotic plaque grows and begins to impede the flow of blood an intervention is needed 
to either re-open the artery lumen or re-route blood around the blockage.  Treatments for intimal 
calcification depend on the severity of the diseased artery, the location of the blockage as well as 
other factors.  Age and the overall health of the patient are also important factors that determine 
the treatment used.  The most common treatment options are balloon angioplasty, stent and 
bypass surgery. 
2.1.1.1 Balloon Angioplasty 
Balloon angioplasty is the most commonly used treatments for less severely calcified arteries.  
This procedure involves the use of a balloon on a catheter fed through the artery to the site of 
calcification where the balloon is inflated to break up the plaque for lumen reopening.  While this 
procedure is minimally invasive and often used, there are drawbacks to it.  Restenosis is a 
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renarrowing of the lumen following the angioplasty procedure.  Usually when the lumen is 
opened during the angioplasty procedure, more damage is done to the diseased artery causing an 
increased inflammatory response, proliferation of cells and resulting in a more severe 
calcification than that which was originally treated. 
 
Figure 6.  Schematic shows how balloon angioplasty works to re-open lumen of a diseased 
artery. 
(http://www.keepingyouwell.com/CareAndServices/InterventionalRadiology/BlockedLegAr
teries.aspx) 
 
 
 
2.1.1.2 Stent 
The use of stents began in an attempt to prevent restenosis.  A stent is a wire mesh placed over 
the balloon which remains in the artery following balloon angioplasty.  The stent is intended to 
remain in the artery to keep the lumen open.  Restenosis still occurs with the use of stents.  More 
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recently drug eluting stents have proven to be more effective in preventing the occurrence of 
restenosis [27]. 
 
 
Figure 7.  Stent remains in place after deployment of balloon to keep lumen open. 
(http://www.lifespan.org/adam/graphics/images/en/19006.jpg) 
 
2.1.1.3 Bypass Surgery 
Bypass surgery is a procedure used to treat the most severely blocked arteries.  It uses a synthetic 
graft or autologous vein to redirect the flow of blood around the area obstructed by calcification.  
Autologous grafts are more often used to bypass smaller arteries and synthetic grafts are more 
useful for larger arteries.  The use of synthetic grafts versus autologous grafts depends on the 
availability of patients‟ veins or arteries for grafting.   
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There are several limitations to this treatment.  The availability of autologous grafts is the most 
limiting factor.  Also synthetic grafts are very prone to thrombosis and have issues with 
anastomosis at the site of graft attachment.  
 
These treatments are all used today even though each one has its own limitations and does not 
completely eliminate the reoccurrence of calcification. Currently there is no treatment for 
vascular calcification available that is cell based and completely reverses elastin calcification. 
 
Figure 8.  Bypass procedure uses a graft to direct blood flow away from the blockage. 
(https://www.beaumonthospitals.com/files/health-library/images/em_2405.gif)  
 
2.2 Medial Calcification 
Medial arterial calcification is the mineral deposition in arteries and occurs independently of 
atherosclerotic plaque [24].  Medial calcification, which is calcification of the medial layer, is 
observed with particularly high frequency in disorders like end-stage renal disease and diabetes 
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mellitus.  Renal disease is often associated with diabetes [28, 29].  Patients with renal disease 
experience increased vascular calcification due to elevated levels of serum calcium and phosphate 
[30, 31].  Elevated calcium and phosphorus have led to increased vascular calcification in animal 
studies as well as in vitro studies [28, 32].  Human aortic smooth muscle cells cultured in media 
containing increased phosphate concentrations showed increased mineral deposition as well as 
increased expression of osteogenic markers [33, 34].  Diabetes increases the occurrence of 
vascular calcification in many ways including oxidized LDLs which can activate macrophages 
and increased glucose concentrations which induce the generation of reactive oxygen species [28, 
29, 35-37].  Although renal disease is often associated with diabetes and both diseases affect 
vascular calcification in different ways, they both are associated with inflammation which greatly 
affects vascular calcification.  Both diabetes and chronic kidney disease have been recognized as 
pro-inflammatory diseases and increase a particular cytokine which has pro-osteogenic 
properties, tumor necrosis factor-alpha (TNF-α) [28].  In vitro calcifying vascular cells cultured 
with TNF-α show an increased mineral deposition and alkaline phosphatase activity [38].  The 
cells also undergo morphological changes from smooth muscle cells to osteoblast-like cells.  A 
patient with diabetes is likely to eventually have chronic renal disease and is very likely to have 
increased vascular calcification compared to a patient without diabetes [28]. 
 
Another name for medial calcification is Monckeberg‟s sclerosis which affects arteries less prone 
to develop atherosclerosis [24] and is typically associated with elastin calcification [26].  Medial 
calcification involves a spontaneous phenotypic change of smooth muscle cells to an osteogenic 
phenotype.  It is also associated with the presence of bone morphogenic proteins (BMPs) which 
are normally expressed exclusively by the bone forming cell, osteoblasts.  Calcification and 
degradation of elastin is also associated with the progression of medial calcification.  The current 
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treatments available are not for medial calcification.  Elastin calcification is irreversible and does 
not spontaneously regress. 
 
Figure 9.  Monckeberg’s sclerosis only affects the medial layer of the artery. 
(http://library.med.utah.edu/WebPath/COW/COW086.jpg) 
 
3. Vascular Calcification Resembles Bone Mineralization 
It was first reported by Virchow in 1863 that arterial calcification was very similar to that of bone 
mineralization [39] and many recent studies have shown the presence of bone cells [40] and bone 
proteins in calcified vascular matrix as well as fully formed bone tissue has also been found in 
calcified human aortic valves [41].  Bone matrix proteins (BMPs) and matrix vesicles which give 
rise to crystallization at low ionic concentrations of calcium and phosphate and both are present 
in calcified valves and atherosclerotic lesions [41].  There are numerous publications which 
examine the presence of bone markers in vascular calcification.  I will summarize different 
studies that have shown evidence of vascular calcification resembling bone mineralization.  
 
Calcification 
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 A study by Jeziorska concluded that the presence of osteoid, mineralized osteocytes, and 
multinucleated osteoclasts in atherosclerotic plaque demonstrated bone formation [42].  
Hydroxyapatite which is the inorganic phase of bone formation has been found in calcified 
atherosclerotic plaques [4, 39, 40].  Both intimal and medial calcification show evidence of bone 
mineralization by the presence of  osteoblast transcription factor core binding factor-α1(CBFA-1) 
[27] [43].  In particular, alkaline phosphatase (ALP), bone sialoprotein (BSP), matrix gla protein 
(MGP), osteocalcin (OCN), osteonectin, osteopontin (OPN) and bone morphogenic protein-2 
(BMP-2) have been found in calcified arteries [5, 44-46].  The presence of these bone proteins 
lead to the hypothesis that vascular calcification is similar to bone mineralization because of their 
importance in osteogenesis [45].  ALP increases the growth of hydroxyapatite while osteonectin 
binds both collagen and hydroxyapatite [5].  OCN and BSP are produced by osteoblasts and are 
associated with the early phases of bone formation [5, 47, 48].  MGP which is produced by both 
osteoblasts and osteoclasts is known to bind calcium and has a high affinity for hydroxyapatite 
[22].   BMP-2 has the full potential to initiate bone formation [5, 45].   
 
In a 2001 study by Dhore, et al, they examined the presence of bone matrix regulatory proteins in 
human atherosclerotic plaques taken from autopsy and vascular surgery [45].  Their study 
revealed the presence of BMP-2 and BMP-4 in fibrocalcific plaques.  Osteonectin was also 
upregulated in atherosclerotic lesions.  BSP, an early marker for bone formation [47], was only 
detected in more mild, early atherosclerotic plaque but not detectable in the fully formed calcified 
atherosclerotic lesions.  OPG was upregulated in the fibrocalcific plaque signifying the blockage 
of osteoclast activity.   
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Dhore also examined non-diseased tissue and found five bone matrix proteins (MGP, OC, BSP, 
BMP-4 and OPG), but not BMP-2 and OPN which are key proteins for late bone formation.  
These findings suggest that bone regulatory proteins are present throughout the entire 
calcification process of atherosclerotic arteries.  These studies have examined clinically calcified 
arteries and found many bone markers present. 
 
Laboratory experiments have also shown evidence of the similarity between vascular calcification 
and bone mineralization.  Knockout mice studies have also added to argument that bone and 
arteries calcify in the same manner.  By silencing key regulatory bone proteins mice express 
severe vascular calcification.  MGP has some effects on osteoclast function and its knockout mice 
have extensive calcification of aorta including aortic valves [4, 5, 49, 50] and die within about 2 
months [45].  MGP deficient mice also show extensive medial arterial calcium deposition.  MGP 
is also expressed in normal arteries to suggest an inhibitory effect [40].  Mice lacking Smad6, the 
gene known to inhibit BMP-2 signaling, exhibit extensive arterial calcification [40].   
 
In vitro studies have also shown results for the affirmative argument that vascular calcification is 
like bone.  Calcifying vascular cells (CVCs) express BMP-2, OCN, OPN, ALP, osteonectin and 
collagen type I under certain stimuli in culture [40, 50, 51].  Bovine aortic smooth muscle cells 
(BASMCs) lose their SMC phenotype in culture with phosphate and express ALP, OCN and 
OPN to appear osteoblast-like [4, 49].  Ultrastructural analysis also confirms the presence of 
hydroxyapatite, calcifying collagen and nodular calcification similar to that observed in calcified 
atherosclerotic plaques in vivo.  
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BMP-2 has also been shown to decrease the expression of SMC markers in vitro after growth 
arrest is induced [43].  Once cell arrest is induced by BMP-2 SMCs lose their native phenotype 
and begin to express an osteoblastic profile.  Vascular SMCs of MGP-deficient mice undergo 
chondrogenic and osteogenic differentiation when treated with BMP-2 [43].  A study by Lee, et al 
showed the time dependent expression of osteogenic markers like Cbfa-1 and alkaline 
phosphatase in close proximity of calcified elastin in a rat subdermal model suggesting that it 
resembles medial vascular calcification [26].   
 
It has been established that vascular calcification is similar to bone through clinical examination, 
knockout mice and in vitro studies.  In order to further examine the link between vascular 
calcification and bone, we should have a more clear understanding of bone and how it functions 
normally. 
 
 
4. Normal Bone Structure and Composition 
Bone is a dynamic tissue which functions in protection of internal organs, provides mechanical 
support for the body, acts as a lever for muscle action, site for hematopoiesis, calcium 
homeostasis and a store of phosphate, magnesium, potassium and bicarbonate [52, 53].  Calcified 
bone contains about 25% organic matrix, 5% water and 70% inorganic material (hydroxyapatite).   
4.1 Types of Bone Mineralization 
There are two mechanisms of bone formation, intramembranous bone formation and 
endochondral ossification.  Intramembranous bone formation involves messenchymal cells 
differentiating directly into osteoblasts which then deposit mineral to create bony structures 
without cartilage formation [54].  This type of bone formation is found during flat bone formation 
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(eg. skull development).  If the differentiation of mesenchymal cells proceeds via chondrocytes to 
form cartilaginous templates of future bone, the process is termed endochondral ossification [54].  
The cartilage template is replaced by invading osteoblasts which allow ossification of the 
structure, which is the common mechanism for mineralization in long bones.   
4.2 Bone Cells 
There are three distinctly different cell types in bone:  osteoblasts, osteocytes and osteoclasts.  
Osteoblasts are the bone-forming cells.  They lay down the extracellular matrix and regulate its 
mineralization [53, 54].  Osteoblasts may become trapped in their own calcified matrix, changing 
their phenotype and developing into osteocytes [54].  Osteocytes are the most abundant cell type 
in bone and create a network of intercellular communication with bone-lining cells (inactive 
osteoblasts).  Osteoclasts are the large multinucleated giant bone-resorbing cells [55, 56].  
Osteoclastic bone resorption initially involves mineral dissolution followed by degradation of the 
organic phase [53].  Bone is continuously being resorbed and rebuilt.  This remodeling process is 
maintained by a homeostasis between osteoblasts and osteoclasts. When a team of osteoclasts dig 
a trench across the surface of a trabecula, it is then refilled by a team of osteoblasts [57] [53] [58]. 
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Figure 10.  Schematic shows the biological function of osteoclasts and osteoblasts. 
(www.glaciermedicaled.com/ bone/bonesc3p5.html) 
 
The main function of osteoclasts is to degrade and resorb mineralized bone matrix. Osteoclasts 
are the only cells capable of dissolving hydroxyapatite.  The osteoclasts migrate to the resorption 
site and form a sealing zone under the cell.  The resorption cycle begins with dissolution of 
crystalline hydroxyapatite and organic matrix rich in collagen.  Integrins are proposed to play an 
important role in this resorption.  Integrin αvβ3 in particular has a high affinity for denatured 
collagen type I and has been found in the ruffled border of osteoclasts as well as the plasma 
membrane and various intracellular vacuoles [59].  Horton showed that inhibition of integrin αvβ3 
was effective in inhibiting bone resorption [60]. Hydroxyapatite crystals are dissolved by targeted 
secretion of acids such as hydrochloric acid (HCl) through the ruffled border into the resorption 
lacuna [61].   
Osteoclast 
Osteoblasts 
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The resorption lacuna is an extracellular space between the ruffled border membrane and bone 
matrix which is sealed from the surrounding environment by a sealing zone.  Proton pumps at the 
ruffled border and intracellular vacuoles maintain an acidic environment in the resorption lacuna.  
Carbonic anhydrase II is essential for the function of the proton pumps [62].   
 
 
Figure 11.  Diagram shows the mechanism of osteoclastic bone resorption. 
(http://a248.e.akamai.net/7/248/430/20040414150433/www.merckfrosst.ca/e/research/r_d/fut
ure_challenges/images/bone_diagram.gif) 
 
 
After the bone mineral phase is solubilized, the organic matrix is further degraded by proteolytic 
enzymes.  Two classes of proteolytic enzymes are involved in the degradation process lysosomal 
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cysteine proteinases and matrix metalloproteinases, in particular Cathepsin K and MMP-9 or 
gelatinase B, respectively [63, 64].  Cathepsin K has been shown to degrade collagen type I [65].  
Once degradation is complete, the byproducts are removed from the resorption lacuna through a 
transcytotic vesicular pathway of the ruffled border to the functional secretory domain where they 
are liberated into the extracellular space.  Tartrate Resitant Acid Phosphatase (TRAP) [66] is 
localized in these transcytotic vesicles of resorbing osteoclasts [3].  
 
Osteoclasts are similar to macrophages because they are derived from the same lineage[67].  Salo 
reported that osteoclasts and macrophages have similar transport pathways [68]. The monocyte 
lineage of hematopoeitic stem cells from the bone marrow can differentiate to osteoclasts, 
macrophages or dendritic cells depending on its cytokine exposure early in the differentiation 
process [69, 70] [71-73].  A promyeloid precursor will differentiate into an osteoclast if it is 
exposed to Receptor activator of nuclear factor-kB ligand (RANKL) [61, 74-76] [71].  RANK 
[77], its ligand (RANKL) and osteoprotegrin (OPG) are all members of the tumor necrosis factor 
(TNF) ligand and receptor signaling family [77, 78].  RANKL is a trans-membrane protein of 
osteoblasts, marrow stromal cells, T-lymphocytes and other ostoeoblastic lineage cells [77, 79] 
[80] [81] [82].  RANKL also exists in a soluble form (sRANKL) once cleaved from the cell 
surface or secreted by T cells [79, 83, 84].  RANKL binds to RANK, which is expressed on pre-
osteoclasts.  The binding is essential for all aspects of osteoclast function such as differentiation, 
maturation, fusion, survival and activity [77, 79].  RANKL expression in the osteoblast lineage is 
baseline until upregulated by 1,25-dihydroxyvitamin D3 and dexamethosone [79, 85-87].  These 
osteolytic factors also inhibit OPG expression.  OPG in known to inhibit osteoclastogenesis and it 
does so by inhibiting the binding of RANKL to RANK [79, 83].  OPG is produced as a soluble 
decoy of RANKL [77].  Bone marrow stromal cells and osteoblasts produce membrane bound 
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and soluble RANKL to stimulate osteoclast differentiate.  This known phenomenon leads us to 
believe that osteoclasts and osteoblasts are coupled, but little is known about the exact 
mechanism of their coupling and communication.  OPG is a soluble factor produced by some 
cells that strongly inhibits osteoclast formation in vitro and in vivo.  OPG prevents binding of 
RANKL to its receptor RANK [88].   
 
Figure 12.  The RANK/RANKL/OPG system is essential in osteoclast differentiation and 
inhibition [43]. 
 
Bone marrow is the source of osteoclast precursors.  Hematopoiesis, regulation and production of 
mature blood cells from primitive stem cells, occurs primarily in the bone marrow[15, 89, 90].  
The bone marrow is also a rich source of stem cells.  It maintains undifferentiated hematopoietic 
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stem cells and supports differentiation of erythroid, myeloid and lymphoid lineages [15, 90].  In 
addition to hematopoietic stem cells, the bone marrow also contains marrow stromal cells or 
mesenchymal stem cells.   
 
Mesenchymal cells are multipotent and able to differentiate into connective tissue    lineages [15, 
90] including fibroblasts, osteoblasts, adipocytes, osteocytes, myocytes and neural cells [91, 92].  
These mesenchymal stem cells have also been found to provide growth factors and matrix 
proteins through cell-to-cell interaction that play a role in maintaining hematopoietic cells [15, 
90, 91].   
 
The hematopoietic cells can be divided into two major groups: myeloid and lymphoid [89, 93].  
The myeloid lineages include erythrocytes (red blood cells), monocyte lineage- derived cells 
(macrophages, osteoclasts, and dendritic cells), granulocytes (neutrophils, eosinophils, basophils 
and mast cells) and platelets.  The lymphoid lineage includes thymus-derived T-lymphocytes, 
BM-derived B-lymphocytes and natural killer (NK) cells.   
4.3 Bone Homeostasis 
Bone is an active living tissue constantly remodeling itself.  Normal remodeling allows for the 
formation of new bone by osteoblasts after the removal of old bone by osteoclasts [94].  
Remodeling is also important for the function on bone as a source of calcium and phosphorus.  
This process is particularly important in childhood because it allows bones to grow, but this 
process continues throughout life.  While remodeling is important is normal bone function, 
abnormalities in this process is the primary cause of disease in bone.  Two major forms of bone 
diseases are osteoporosis and osteopetrosis which are both directly related to an imbalance in 
remodeling.   
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4.4 Bone Diseases 
Osteoporosis is the most common bone disease.  The imbalance in the remodeling process by an 
abundance of osteoclast function results in a loss of bone mass and a fragile skeleton.  It is related 
to an increased porosity of the bone caused by increased osteoclast activity.  Patients suffering 
with osteoporosis have reduced bone mass and a high incidence of fracture.  Osteoporosis can be 
localized to a particular region or affect the entire skeleton.  It is mainly a disease of the elderly 
especially post menopausal women.  Osteoporosis is usually brought on by a deficiency in 
calcium, vitamin D and estrogen.  Estrogen deficiency causes an increase in RANKL which is 
directly related to osteoclast function [94].   
 
Osteopetrosis is a condition in which bones are too dense because of a failure of osteoclast 
formation or function.  This is a rare hereditary disease [94].  These dense bones do not remodel 
well in response to mechanical forces or microdamage and are actually weaker and subject to 
fracture. In this abnormality of the remodeling process, the trabecular bone invades the marrow 
space and does not allow enough space for normal formation of blood cells [94].  The balance of 
osteoblasts to osteoclasts is the cause of most bone diseases, which may also be the link between 
vascular calcification and bone mineralization. 
 
5. Link between Vascular Calcification and Bone Mineralization 
 
It has been established that vascular calcification and bone mineralization are very similar, but 
can they be regulated by the same mechanisms? Osteoclasts are the cells which resorb bone and 
an overexpression of them can lead to excessive bone loss or osteoporosis.  In bone, homeostasis 
is maintained through the RANK/RANKL/OPG system [77, 95, 96].   
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RANKL (then called OPGL) was first discovered as a replacement for stromal cells and vitamin 
D3 in osteoclast cell cultures in 1998 by Lacey and associates[83, 97, 98].  They discovered that it 
binds to hematopoeitic progenitors of osteoclast lineage to form and activate osteoclasts in vitro 
along with M-CSF [99].  Before this discovery mature osteoclasts were formed in vitro from bone 
marrow and spleen cells with vitamin D3 and stromal cells [83].   M-CSF (also known as CSF-1) 
is important to osteoclast maturation because it regulates survival, proliferation and 
differentiation of mononuclear cells [99]. Intravenous [83] injections of M-CSF to mice caused 
circulating monocyte counts to increase from 3-30% [99].   
 
All of the RANK/RANKL/OPG system has been found in vascular cells.  OPG deficient mice 
exhibit osteoporosis and medial calcification of aorta and renal arteries [77].  Osteoporosis and 
vascular calcification frequently occur together and share the same risk factors [100].  RANKL is 
expressed in the calcified arteries of OPG (-/-) mice, but undetected in normal, noncalcified 
arteries [79, 84, 101].  OPG is highly expressed in normal arteries [102].  The calcification of 
arteries in OPG knockout mouse occurs without fat deposition as seen in atherosclerosis patients 
[101].  Therapeutic injections of a high dose of recombinant OPG to OPG deficient mice did not 
affect the incidence of arterial calcification [101].  Significantly lower levels of sRANKL were 
observed in patients with severe arterial calcification [77, 100].   
 
Even though calcified arteries are expressing markers of bone formation, there are also markers 
for bone resorption suggesting that there may be a natural attempt by the body to reverse the bone 
mineralization occurring in the arteries.  RANKL is essential for osteoclast survival and it has 
been expressed in a number of vascular tissues [40].  Another osteoclast marker, Cathepsin K, has 
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been found in atherosclerotic plaques [40].  Normal arteries may also produce MGP to prevent 
osteogenic mineralization as suggested by the expression MGP in normal arteries as compared to 
atherosclerotic arteries [22].  One particular study examined the presence of RANKL and OPG in 
explanted atherosclerotic, monckeberg sclerotic and normal arteries [77].  The results show that 
RANKL was expressed diffusely throughout the diseased arteries, but not in the normal arteries.  
OPG was also expressed in close proximity to the site of calcification in the diseased arteries and 
diffusely in the normal arteries 
 
While there are several similarities to vascular calcification and bone, there is one major 
component that is not.  There is no elastin in bone.  Bone markers and cells may have been found 
in calcified arteries but to date there are no findings of elastin proteins in bone.  There is also 
evidence of potential bone resorption in calcified arteries as previously described by the presence 
of osteoclast-specific markers, RANKL and Cathepsin K, being found in calcified arteries.  Can 
bone resorption mechanisms be used to reverse arterial calcification?  Several reviews have also 
pondered this question [50, 103-105].  A review by Massy thoroughly examined the similarities 
between vascular calcification and bone and hypothesized that osteoclast-like cells could be the 
missing link [105].  It is unclear at this time if a local balance of osteoblastic phenotypes to 
osteoclastic phenotypes in calcifying arteries could be tilted to osteoclastic resorption of 
calcification so to restore native arteries there are two ways that this can be achieved; local 
delivery of mature osteoclasts through a gel delivery system close to vascular calcification and 
recruitment of osteoclast progenitors to the site of calcification.  Cell based therapies have been 
used to treat a number of different diseases and may be the answer to vascular calcification.  I 
will outline a brief history of cell therapy, give examples of how it‟s being used today and go 
over its potential as a treatment for vascular calcification. 
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6. Cell Therapy 
Human bone marrow transplants (BMT) were first used in the 19
th
 century sporadically, but the 
modern era began in 1957 by French and Yugoslav physicians [106, 107].  The physicians used 
human BMT to treat workers involved in a nuclear reaction accident.  This same treatment was 
also used again three decades later in the Russian Chernobyl accident.  BMT is now a world wide 
treatment for selected malignant and non-malignant disorders including leukemia, Hodgkin‟s 
lymphoma, cancer (breast, lung and skin), sickle cell and osteopetrosis [106].  BMT can be both 
autologous and allogenic.   
 
There are a few complications associated with patients receiving BMT , most often involving 
infection [107].  One particular complication of allogenic BMT unrelated to infection is graft-
versus-host-disease (GVHD) [108].  GVHD is when the transfer of tissues between individuals 
results in recognition and rejection of the transplant in a host-versus-graft reaction.  This 
phenomena was first noted when irradiated mice were infused with normal spleen and although 
the mice recovered from radiation injury and marrow aplasia they subsequently died with a 
secondary disease consisting of diarrhea, weight loss, skin changes and liver abnormalities [108].  
In 1966 Billingham outlined the requirements for development of GVHD to be: 1. the graft 
contains immune competent cells and host appears foreign to graft and 2. the host cannot mount a 
sufficient immune reaction to graft [107, 108].  A treatment for GVHD consists of 
immunosuppressants post transplant.   
 
Even though BMT has been used for several years many advances have been made to take this 
therapy into the future.  GVHD probability has been drastically decreased with the introduction of 
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T-cell depletion of donor marrow [109].  Another treatment for GVHD is the use of more targeted 
cells with immunoaffinity “positive” selection of CD34+ cells [110].  Human stem/progenitor 
cells have the highest expression of CD34.  Precursors of hematopoietic stromal cells, osteoclasts 
and endothelial cells express CD34.  One draw back to this treatment is that CD34 expression is 
only 1.5% of aspirated bone marrow and monocytes comprise 6-8% of circulating white blood 
cells [106, 110].   
 
Since the first use of BMT, there have been many advances for cell therapy as well as the use of 
other stem cells to treat various diseases.  Stem cell therapy is currently involved in 2442 clinical 
trials [111].  Adult marrow is a potential source of stem cells to treat a wide of degenerative 
diseases and damaged tissues like in osteoarthritis, diabetes mellitus, Parkinson‟s disease, 
ischemic heart disease and retinal degeneration [112-114].  The use of adult stem cells could also 
be used to treat diseases like stress urinary incontinence for which there has only been the 
undesirable treatment of a pelvic sling [115].  Cell based therapies have been used for cartilage 
and tendon repair [116]. 
 
Symptoms of Parkinson‟s disease and retinal degeneration have been alleviated by the use of 
microencapsulated retinal pigment epithelial cells [27] [117] [27].  The cells are maintained in a 
non-dividing state and secrete neutrophic factors to treat both diseases.  The cells also produce 
dopamine and neutrophic support of the basal ganglia to assist in management of Parkinson‟s 
disease.  Neural stem cells have also been used to treat Parkinson‟s disease as well as spinal cord 
injuries [118].  Cell based therapies are showing promise in fetal surgery to treat spina bifida 
using neural stem cells [119].   
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Cell therapy has also been proven as a great treatment in the cardiovascular field.  Stem cell use 
has great potential in treating hearts damaged by myocardial infarction [120].  Transplantation of 
autologous CD31+ and CD34+ cells induced neovascularization and improved ventricular 
function after myocardial infarction in pig and rat models [121]. Endothelial progenitor cells 
isolated from the bone marrow have also been used to achieve cell-based neovascularization in 
damaged myocardium [122].   
 
Cell therapy has proven to be effective for many diseases including those in the cardiovascular 
field.  Transplanted autologous cells have survived and induced improvement in myocardial 
infarction and we are proposing a similar treatment.  We plan to transplant autologous osteoclasts 
which have been matured in vitro and also recruit osteoclast progenitors to the site of 
calcification.  We hypothesize that the osteoclasts would resorb the elastin calcification.  
 
7. Epilogue 
In this literature review, it has been established that vascular calcification is a disease that 
threatens Americans and the treatments available are not effective in reversing its causes.  
Vascular calcification resembles bone with the presence of bone cells which express BMPs as 
well as other important osteogenic markers.  It is also established that osteoclasts are the only 
cells capable to resorb bone hydroxyapatite. The RANK/RANKL/OPG system could be the link 
to reverse elastin calcification.  Cell therapy is also a potential treatment for several diseases and 
has proven effective in a few models.  
 
Below is schematic by Doherty from a publication in which they outlined why osteoclasts may 
the answer to treat vascular calcification.  In the box labeled bone, it details the mechanism in 
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which an osteoclast matures and resorbs bone and the box labeled atherosclerotic plaque is 
depicting the question can osteoclasts do the same to resorb the mineral phase found in vascular 
calcification.  Our research hypothesis is based on the same principle. We hypothesize that a site-
specific delivery of osteoclasts may have the potential to limit or reverse elastin calcification.  We 
also plan to examine the effect of RANKL as a recruiter of osteoclasts to the site of calcification.   
 
Figure 13.  Pictorial depiction of our research hypothesis [50].
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Chapter Three 
 
Projection Rationale 
Hypothesis 
Vascular calcification occurs during physiological aging and is clinically recognized as a major 
risk factor for myocardial infarction, systolic hypertension, heart failure and coronary 
insufficiency caused by loss of aortic recoil. Medial arterial calcification is an active remodeling 
process that involves the deposition of bone-like mineral in close association with elastic fibers. 
Elastin, a major structural protein in the extracellular matrix of arterial walls, provides elastic 
recoil to the arteries. Increasing evidence suggests that vascular calcification share features with 
skeletal bone formation such as presences of bone-specific proteins, osteoblast like cells, bone 
matrix deposition. Bone morphogenetic proteins (BMPs) and bone cells (osteoblast and 
osteoclasts) have been found in explanted atherosclerotic plaques.  In bone, a homeostasis is 
maintained by its two major cell types; osteoblasts and osteoclasts.  Osteoblasts form new bone 
matrix and osteoclasts, multinucleated giant cells which are derived from bone marrow progenitor 
cells, are responsible for bone resorption.  As active bone remodeling and mineral deposition is 
observed in arteries, we wanted to test whether osteoclast cell based therapy could be used to 
resorb vascular elastin specific calcification.  We would use a two pronged approach.  Initially we 
will attempt to site specifically deliver autologous osteoclasts which have been matured in vitro to 
the calcification site.  We will also attempt to recruit native osteoclast progenitors to the site of 
calcification.  We hypothesize that a site-specific delivery of osteoclasts may have the potential to 
limit or reverse elastin calcification.   
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Specific Aims 
 
Aim I: Evaluation of media supplements and their effect on osteoclast differentiation and 
elastin demineralization in vitro 
Studies were performed to determine the most effective media supplements for osteoclast 
differentiation.  Bone marrow progenitor cells (BMPCs) were incubated with different media 
supplements intended to induce differentiation into osteoclasts. We also examined the effect of 
these differentiated cells on elastin demineralization in vitro.  
 
Aim II: Evaluation of mature osteoclasts (OCs) derived from BMPCs in vitro and their 
effect on elastin demineralization  
In the previous aim we determined the best media supplementation for differentiation of BMPCs 
into OCs and we showed that during differentiation these cells can demineralize calcified elastin.  
For this aim we examined if OCs have the same effect if previously differentiated to maturity. 
BMPCs were differentiated into mature OCs by incubation with Vitamin D3/Retinioc Acid media 
supplementation. Mature osteoclasts derived from bone marrow progenitor cells were used to 
demineralize calcified elastin.  
 
Aim III: Evaluation of osteoclasts derived from bone marrow progenitor cells to limit 
elastin calcification in vivo 
In vitro studies shown that OCs differentiated from BMPCs were effective at demineralizing 
calcified elastin during and post differentiation. Next, we wanted to examine whether local 
delivery of OCs can inhibit elastin calcification in vivo. Mature osteoclasts derived from BMPCs 
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were incorporated into collagen gels and implanted subdermally close to purified porcine elastin 
implants. The progression of calcification in presence of OCs was studied.   
 
Aim IV:  Evaluation of site-specific delivery of osteoclasts to reverse elastin calcification in 
vivo 
Previous aims examined OCs ability to demineralize calcified elastin in vitro and their ability to 
limit the progression of elastin calcification in vivo. In a clinical settings, arteries would be 
calcified before therapy begins. Thus, we wanted to examine whether OCs can limit or resorb 
already established elastin calcification in vivo.  We first induced elastin calcification by 
subdermally implanting purified elastin forone week. We reopened the implant site and then 
delivered mature OCs directly to the site for elastin demineralization. 
 
Aim V: Evaluation of RANKL as a recruiter of native osteoclasts to demineralize calcified 
elastin in vivo 
One approach would be to recruit native monocytic cells to the site and mature them to osteoclast 
like cells rather than isolating cells from bone marrow and then delivering them to the site. Thus, 
for this aim we attempted to recruit native OCs to the site of elastin calcification.  In a clinical 
setting, it would require less surgical manipulation to recruit native cells than transplanting cells 
differentiated in vitro. Elastin was subdermally implanted and allowed to calcify for one week. 
RANKL and OPG (agents that are known to attract osteoclast like cells) were then delivered 
directly to the implant site to recruit and mature monocyte cells to OCs for elastin 
demineralization. 
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Aim VI:  Evaluation of osteoclasts to reverse arterial elastin-specific calcification in an 
abdominal aortic injury model 
This aim was most clinically relevant approach to our hypothesis. We used a rat aortic injury 
model where native artery was allowed to calcify in the medial layer similar to what is seen in 
human disease of arteriosclerosis.  For this study calcium chloride was applied periadventitially 
for fifteen minutes to the abdominal aorta (infra renal) of Sprague Dawley rats to cause medial 
calcification of the aorta. Mature osteoclasts were then delivered periadventitially to the aorta to 
reverse elastin calcification. 
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Chapter Four 
Evaluation of Media Supplements and their Effect on Osteoclast Differentiation and 
Elastin Demineralization in vitro 
Introduction 
We hypothesized that mature allogenic osteoclasts (OCs) derived from bone marrow 
progenitor cells (BMPCs) can be delivered to the site of calcification to regress vascular 
calcification. There are two different methods used to differentiate OCs from BMPCs. 
Vitamin D3 with retinoic acid has been used for a long time for OC differentiation [123]. 
More recently in literature Receptor activator of nuclear factor-kB ligand (RANKL) has 
been extensively used for OC differentiation since its discovery in 1998 [83]. We wanted 
to test which method would give us a higher population of osteoclast cells.  
Materials and Methods 
Progenitor Cell Isolation 
Bone Marrow Progenitor Cells (BMPCs) were isolated from adult Sprague-Dawley rats 
by flushing the marrow space of femurs and tibias with warm Iscove‟s media with 10% 
fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Ab/Am) (Sigma, St. Louis, 
MO).  The flushed cells are filtered through a 40 µm cell strainer (BD, Franklin Lakes, 
NJ) and centrifuged. The cells are resuspended in Iscove‟s culture media (Iscove‟s media 
with 20% FBS and 1% Ab/Am) and layered onto Ficoll-Paque gradients (Amersham 
Biosciences, Piscataway, NJ) then centrifuged. The mononuclear cell layer was isolated 
from the gradients and cultured in Iscove‟s culture media. 
Differentiation of BMPCs to OCs 
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RANKL Concentration 
To examine the effect of different concentrations of RANKL on the differentiation of bone 
marrow progenitors to osteoclasts, human RANKL (BioVision, Mountain View, CA) was added 
to the culture media at three different concentrations; 5 ng/ml, 10 ng/ml and 20 ng/ml.  In these 
conditions, bone marrow progenitor cells differentiate into mature osteoclasts after approximately 
fourteen days.   
Vitamin D3+Retinoic Acid vs RANKL 
To examine the effect of Vitamin D3+Retinoic Acid vs RANKL on the differentiation of bone 
marrow progenitors to osteoclasts, all-trans retinoic acid (Sigma, St. Louis, MO) and 1,25-
Dihydroxyvitamin D3 12 (Sigma, St. Louis, MO) added in 10
-6
M concentrations to culture media 
and 10 ng/ml RANKL separately.  In these conditions, bone marrow progenitor cells differentiate 
into mature osteoclasts after approximately fourteen days.   
Flow Cytometry 
Differentiated cells were tripsinized and washed twice in DLB buffer (DPBS with 1% 
bovine serum albumin).  Cells were then fixed in 2% paraformaldehyde for 30 minutes.  
Cells were permeabilized with 0.1% Triton for 5 minutes followed by a wash in staining 
buffer.  Cells were stained with 0.5uM calcein (Invitrogen, Carlsbad, CA) for 15 minutes 
at 37⁰C in the dark.  After a wash in staining buffer (DPBS with 2% bovine serum 
albumin and 0.05% sodium azide), the cells were stained with Cathepsin K primary 
antibody (Abcam, Cambridge, MA) for one hour in the dark followed by three washes in 
staining buffer.  Cells were then stained with secondary antibody of Alexa Fluor 594 
(InVitrogen, Carlsbad, CA) for 15 minutes in the dark, followed by a wash in staining 
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buffer.  We used the Agilent 2100 bioanalyzer to perform microchip flow cytometry 
analysis and the Agilent Cell Fluorescence kit. (Agilent Technologies, Santa Clara, CA). 
Cell Phenotype Verification 
Differentiated OCs were stained for tartrate-resistant acid phosphatase (TRAP), which is 
a stain specific for OCs, using a TRAP kit following manufacturer‟s instructions (Sigma, 
St. Louis, MO). 
Bioactivity of Osteoclasts 
BMPCs (5x10
4
 cells/gel) were seeded onto hydroxyapatite coated discs (BD, Franklin 
Lakes, NJ), which simulate bone, and cultured with RANKL and Vitamin D3/retinoic 
acid media supplementation separately for fourteen days.  After culture, media was 
removed and then discs were rinsed with deionized water three times.  Discs containing 
cells were bleached by adding 1 mL of bleach solution (6% NaOCl, 5% NaCl) with 
agitation at 37°C.  Discs were again washed three times with deionized water then 
allowed to air dry. The discs were stained for calcium using the von Kossa staining 
procedure to reveal any resorption pits (observed microscopically) formed by the OCs. 
Purification of Porcine Elastin 
Elastin was purified from fresh porcine aorta tissue obtained from a local abattoir 
following a procedure originally described by Partridge [124].  Porcine aortas were 
transported from the local abattoir in sterile 0.9% NaCl on ice.  The tissue was cut into 2 
mm strips and washed several times in distilled water.  The tissue was then shredded and 
washed in 0.9% NaCl until the content of soluble proteins was undetectable by BCA 
assay (Pierce, Rockford, IL).  Collagen denaturation was achieved by numerous cycles of 
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autoclaving. The tissue was then dried to remove any remaining lipids with ethanol and 
diethyl ether yielding pure elastin.  The pure elastin was stored at 4°C. 
 Subdermal Elastin Implantation 
Previously purified porcine elastin was hydrated 1-2 hours prior to surgery in sterile 
Phosphate buffered saline (PBS) without calcium and magnesium (Mediatech, Manassas, 
VA).  Juvenile male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) 
weighing ~30 g were placed under general anesthesia (2% isoflurane) then two incisions 
were made on the back above the shoulder blades (left and right side) as shown in Figure  
followed by the formation of subdermal pockets by blunt dissection.  The hydrated elastin 
~30 mg was packed into sterile 1cc syringes with the tips removed.  The elastin was 
injected into the subdermal pockets and the incisions were closed with staples.  The 
animals were humanely euthanized using CO2 asphyxiation at day seven.   
 
 
 
Figure 14. Location of subdermal elastin implants. 
Calcified Elastin Incorporation into Collagen Gel 
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Explanted calcified elastin was homogenized in 100% ethanol then the ethanol was 
evaporated using a continuous stream of sterile nitrogen gas. A collagen solution 
previously prepared with eight parts PureCol® (Advanced BioMatrix, San Diego, CA), 
one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium Hydroxide 
(NaOH) in a 50 mL centrifuge tube on ice.  The mixture was vortexed vigorously and pH 
adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl).  Homogenized elastin was 
added to the collagen mixture at a concentration of 2.5mg/ml then 0.5 ml of 
elastin/collagen mixture was added to well plates and allowed to solidify sterilely at 37°C 
for ~30 minutes. Once solid, differentiated OCs (5x10
4
 cells/gel) were seeded onto the 
gels and cultured for fourteen days. 
Calcium Analysis 
The media was removed from the gels which were then washed three times with 
deionized water and frozen at -80°C and lyophilized.  The dried samples were hydrolyzed 
in 6 N HCl in a boiling water bath.  The hydrochloric acid was evaporated using a 
continuous stream of nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was 
measured using atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer, 
Norwalk, CT).  
Statistical Analysis 
Data are reported as means ± SEM. Student‟s t-test was used to determine differences 
between groups. Data are termed statistically significant when p<0.05.  
Results 
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BMPCs cultured for 14 days were 43%, 41%, and 39% differentiated to OCs at 10, 15, 
and 20 ng/ml RANKL respectively (Figure 15).  As no significant difference was 
observed for the different concentrations, the lowest concentration (10 ng/ml) of RANKL 
was used for further experiments.   
 
Figure 15. Characterization of OCs differentiated from BMPCs by incubation in varying 
concentrations of RANKL by flow cytometry. 
Next, the two methods for differentiation were compared by culturing BMPCs in Vitamin 
D3 and retinoic acid (10
-6
M) and RANKL (10 ng/ml) separately for 14 days and the 
amount of differentiation was measured using flow cytometry.  BMPCs incubated with 
Vitamin D3 with retinoic acid differentiated into OCs more than those incubated in 
RANKL.  Even though the same amount of cells were seeded Vitamin D3 incubation 
expressed more than 2X more positive cells than RANKL (Figure 16).  
A B 
C D 
A: BMPC Only B: 10 ng/ml RANKL C: 15 ng/ml RANKL D: 20 ng/ml RANKL  
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Figure 16. BMPCs incubated with Vitamin D3 retinoic acid (B) were 2X more positive 
for the Cathepsin K antibody than those differentiated with RANKL (C). 
Cells cultured with both methods were positively identified as OCs by tartrate resistant 
acid phosphatase (TRAP) staining as evidence by the reddish-brown stain (Figure 17).   
 
 
A: BMPC-C B: BMPC-D3R C: BMPC-RANKL 
A B 
C 
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Figure 17. BMPCs differentiated into OCs with Vitamin D3 and retinoic acid (top) and 
RANKL (bottom) were all positively TRAP stained. 
For validation of mineral-resorptive abilities, BMPCs were seeded onto hydroxyapatite 
discs, which simulate the mineral phase of bone and allow visualization of resorptive 
activity. After 14 days in culture with both differentiation methods, resorption pits were 
clearly visible. Both methods for obtaining osteoclasts from rat bone marrow were 
effective at inducing hydroxyapatite dissolution by the cells. Vitamin D3 incubation did 
cause more resorption pits than RANKL (Figure 18).  
BMPC-D3R 
BMPC-RANKL 
10X 
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Figure 18. BMPCs cultured with and without (B) media supplements are capable of 
forming resorption pits but Vitamin D3 with retinoic acid (D) caused more cells to form 
resorption pits than RANKL (C). 
BMPCs without any differentiation were not able to remove calcium from the calcified 
elastin. Osteoclasts differentiated by Vitamin D3 with retinoic acid and RANKL both 
significantly induced demineralization of calcified elastin (p<0.05) (Figure 20). Elastin 
content was analyzed by desmosine analysis performed by radio immunoassay. There 
was no reduction in desmosine content during demineralization by either method of 
differentiation clearly indicating that elastin was not significantly degraded during 
demineralization process (Figure 20). 
 
 
 
 
A B 
C D 
A: Disc w/o cells B: BMPC-C  
C: BMPC-RANKL D: BMPC-D3R 
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Figure 20. BMPCs cultured in Vitamin D3 with retinoic acid and RANKL significantly 
reduced calcium content (top) in calcified elastin but did not reduce elastin content 
(bottom) in the process (n=4). 
Discussion 
In order to prove our hypothesis that mature allogenic osteoclasts (OCs) derived from 
bone marrow progenitor cells (BMPCs) can be delivered to the site of calcification to 
regress vascular calcification, we had to test the most common methods for OC 
differentiation found in literature: Vitamin D3 with retinoic acid and RANKL 
(Thavarajah, 1991; Lacey,1988). Osteoclasts are of hematopoietic origin and their 
precursors can be differentiated into mature OCs in vitro under specific conditions. 
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The percentage of cells differentiated into mature OCs was measured using flow 
cytometry. Vitamin D3 and RANKL as media supplements are both effective in 
differentiating BMPCs into OCs as shown by flow cytometry results, however, 
Vitamin D3 was more effective and provided more OCs than RANKL. Cells 
differentiated by both methods were stained TRAP positive by revealing a reddish-
brown stain further verifying the differentiation into mature osteoclasts (Yasuda, 
1998). The bioactivity of the cells during differentiation was analyzed by the ability 
of the cells to form resorption pits on hydroxyapatite coated discs. The coating on the 
discs simulate the mineral matrix of bone and since OCs are the only bone resorbing 
cells, their formation of resorption pits indicate successful differentiation into mature 
OCs (Contractor, 2005). OCs differentiated with Vitamin D3 created more resorption 
pits than those differentiated in RANKL.  
Given the similarities of vascular calcification and bone, we next examined the ability 
of OCs to resorb vascular calcification. Osteoclasts differentiated from BMPCs using 
both Vitamin D3 and RANKL as media supplements were effective in demineralizing 
calcified elastin, while undifferentiated cells were ineffective clearly showing that 
prior differentiation to OCs is required for cells to remove mineral from elastin. 
Although the use of OCs as a treatment for vascular calcification is quite novel one of 
the side effects could be that osteoclasts will degrade extracellular matrix of 
vasculature while resorbing the mineral. OCs are known to secrete ECM degrading 
enzymes such as MMPS and cathepsin that can degrade elastin. We evaluated if 
resoprtion of elastincalcification by OCs would cause any damage to elastin by 
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desmosine assay. Others have shown that desmosine assay is a marker of elastin 
degradation (lower the desmosine content, the higher is the degradation) (Starcher, 
1977). Our desmosine data showed no alteration after OCs incubation suggesting that 
during demineralization process, the elastin was not degraded. This data is 
encouraging as shows that we can use OCs cell therapy for demineralization without 
causing too much damage to the existing vascular ECM. We clearly need to show that 
collagen, another important ECM component, is also not degraded by OCs.  
The comparison of the two differentiation methods for OCs is not well documented in 
the literature. Ours was first of its kind of side-by-side comparison of these two 
methods. RANKL is the newer, more widely used method for OC differentiation but 
as our results have shown the older method of Vitamin D3 with retinoic acid is more 
effective at OC differentiation. The examination of both methods and their effect on 
demineralization of calcified elastin showed no difference between the methods. 
Thus, both methods create OCs that can resorb mineral from elastin. 
In conclusion, Vitamin D3 and RANKL as media supplements are both effective in 
differentiating BMPCs into OCs, however, Vitamin D3 was more effective and 
provided more OCs than RANKL. Osteoclasts differentiated from BMPCs using both 
Vitamin D3 and RANKL as media supplements were effective in demineralizing 
calcified elastin and during the demineralization process, the elastin was not degraded 
as assessed by desmosine analysis. 
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Chapter Five 
 
Evaluation of Mature Osteoclasts Derived from Bone Marrow Progenitor Cells in 
vitro and Their Effect on Elastin Demineralization 
 
Introduction 
As shown in the previous chapter, we examined the two most common differentiation 
methods for OC differentiation from BMPCs [83, 123] and  showed that BMPCs could 
be differentiated into OCs when cultured with Vitamin D3 and RANKL media 
supplements and effectively formed resorption pits as well as demineralized calcified 
elastin during differentiation.  Vitamin D3 appeared to be more effective than RANKL for 
differentiation of BMPCs into OCs, therefore; Vitamin D3 was our chosen method for 
osteoclast differentiation for further studies. For those studies, differentiating media was 
present when BMPCs were contacted with elastin and we allowed them to differentiate 
during demineralization. For this aim, we decided to see if  
OCs would have the same effectiveness in demineralization when differentiated to 
maturity first. This will be more clinically relevant as bone marrow cells can be obtained 
from the patients and matured to OCs in vitro prior to their delivery to the pathologic 
calcification site. 
 
Materials and Methods 
Osteoclast Isolation 
Bone Marrow Progenitor Cells (BMPCs) were isolated from adult Sprague-Dawley rats 
by flushing the marrow space of femurs and tibias with warm Iscove‟s media with 10% 
fetal bovine serum (FBS) and 1% antibiotic/antimycotic (Ab/Am) (Sigma, St. Louis, 
MO).  The flushed cells are filtered through a 40 µm cell strainer (BD, Franklin Lakes, 
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NJ) and centrifuged. The cells were resuspended in Iscove‟s culture media (Iscove‟s 
media with 20% FBS and 1% Ab/Am) and layered onto Ficoll-Paque gradients 
(Amersham Biosciences, Piscataway, NJ) then centrifuged. The mononuclear cell layer 
was isolated from the gradients and cultured in Osteoclast Culture Media (Iscove‟s 
culture media with all-trans retinoic acid and dihydroxyvitamin D3 (Sigma, St. Louis, 
MO) added in 10
-6
M concentrations). Mature osteoclasts (OCs) were differentiated from 
BMPCs by culturing them with defined media for 14 days. Differentiated cells attached 
to the flask while undifferentiated cells remain unattached and floated off. 
Histology 
Mature OCs were seeded onto sterile glass slides and cultured in osteoclast culture media 
overnight for sufficient adherence.  The media was removed after overnight culture and 
the slides were washed in warm PBS to remove any un-adhered cells and other debris. 
The OCs were then stained following the standard Hematoxylin and Eosin (H&E) 
staining procedure.  OCs were also stained for tartrate-resistant acid phosphatase 
(TRAP), which is a stain specific for OCs, using a TRAP kit (Sigma, St. Louis, MO). 
Bioactivity of Osteoclasts and Demineralization of Calcified Elastin 
The experiments were performed the same as in the previous chapter only the cells were 
differentiated to maturity before being seeded. 
Results 
 
Osteoclast morphology was determined by H&E staining and phenotype was determined 
by TRAP staining (Figure 21). Large cells with multiple nuclei were found in H&E 
staining indicative of osteoclasts.  TRAP gives reddish-brown stain specific to 
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osteoclasts. Several multi nucleated cells were found to stain for TRAP also indicating 
osteoclasts.  
 
Figure 21.  Morphology and Phenotype verification of OCs differentiated by VitaminD3 
with retinoic acid by H&E staining (A&B)  and TRAP staining (C&D).  
Biological function of the differentiated cells was verified by their ability to form 
resorption pits on hydroxyapatite discs.  The hydroxyapatite coated discs simulate bone 
and the OCs form pits by resorbing the hydroxyapatite layer of the discs (Figure 22).  
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Figure 22. Mature OCs differentiated using VitaminD3 with retinoic acid form early 
resorption pits by day 7 (B) and fully formed pits by day 14 (C&D). No cells were seeded 
on disc in A. 
Calcium analysis showed that previously matured OCs were able to demineralize 
calcified elastin (Figure 23). Media from the culture study was also analyzed for calcium 
levels and results showed that demineralization of calcified elastin by OCs increased the 
calcium levels in the media. 
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Figure 23. OCs have the ability to demineralize calcified elastin (n=4).  
Discussion 
 
BMPCs were differentiated in two weeks into mature OCs using vitamin D3/retinoic acid 
supplementation before use in any experiments.  The differentiated cells demonstrated all 
of the morphologic and phenotypic aspects of OCs with the multiple nuclei shown by 
H&E staining and positive reddish brown stain by TRAP staining [125].  The mature 
OCs were also biologically active and formed resorption pits on hydroxyapatite discs 
further verifying the mature differentiation into OCs [126].  
 It is well documented that bone and vascular calcification are quite similar and given that 
OCs are the only bone resorbing cells, we evaluated if OCs would be effective at 
demineralizing calcified elastin if differentiated to maturity first. The use of OCs as a 
treatment for vascular calcification is a very new concept. In the previous chapter we 
showed that during differentiation OCs were able to demineralize calcified elastin and for 
this aim we explored the effectiveness of mature OCs. We did see similar results for the 
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OCs that were in the differentiation phase and those that were maturely differentiated. 
The mature OCs act the same as OC precursors because even though they are mature, 
they are not activated. OCs are not activated until in the presence of mineralization. This 
is also confirmed by the formation of resorption pits by BMPCs with any media 
supplementation. Literature also shows that OCs produce factors for activation 
themselves [80].  The maturely differentiated cells were effective at demineralizing 
calcified elastin. In conclusion, we have shown that OCs are able to resorb calcification 
during differentiation and after maturity.  
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Chapter Six 
Evaluation of Osteoclasts Derived from Bone Marrow Progenitor Cells to Limit 
Elastin Calcification in vivo 
Introduction 
Previous chapters have focused on the in vitro evaluation of our hypothesis that a site-
specific delivery of OCs will demineralize calcified vascular elastin.  We have shown that 
BMPCs can be differentiated into OCs using Vitamin D3 with retinoic acid media 
supplementation.  We have also shown that these cells are effective at demineralizing 
calcified elastin in vitro.  
The calcified elastin used for the previous in vitro studies was calcified using a subdermal 
calcification model which uses juvenile rats.  In vitro experiments shown promising 
results, however, in such experiments OCs were directly placed over calcified elastin. It 
is much more complex when OCs need to resorb mineral in vivo. They have to survive at 
the site and not altered by inflammatory and remodeling responses.  For this aim we 
examined the effectiveness of OCs to limit the progression of elastin calcification in vivo. 
Material and Methods 
This experiment uses several methods that are the same as those used in previous 
chapters.  Osteoclasts were isolated then cultured to maturity and porcine aortic elastin 
was purified the same as before.  
Osteoclast Labeling and Collagen Gel Encapsulation 
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE 
(Molecular Probes, Carlsbad, CA). Once labeled, the cells were added to a collagen 
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solution previously prepared with eight parts PureCol® (Advanced BioMatrix, San 
Diego, CA), one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium 
Hydroxide (NaOH) in a 50 mL centrifuge tube on ice.  The mixture was vortexed 
vigorously and pH adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl).  Previously 
purified porcine aortic elastin was then added to cell/collagen mixture. The 
elastin/cell/collagen mixture was taken up into 1 ml syringes (with tips removed for 
easier implantation) with a cell concentration of 2.1x10
4 
cells/gel with 30 mg elastin/gel 
and allowed to solidify sterilely at 37°C for ~30 minutes. Control groups include elastin 
in collagen gel (30mg/gel) and OCs in collagen gel (2.1x10
4 
cells/gel). Once solid, the 
collagen gels were sterilely transferred to the surgery suite for implantation. 
Subdermal Implantation 
Juvenile male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) weighing ~30 
g were placed under general anesthesia (2% isoflurane) then two incisions were made on 
the back above the shoulder blades (left and right side) as shown in Figure 24 followed 
by the formation of subdermal pockets by blunt dissection.  The gels (n=3) were injected 
into the subdermal pockets and the incisions were closed with staples.  The animals were 
humanely euthanized using CO2 asphyxiation at days one, three and seven. 
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Figure 24. Location of subdermal elastin implants. 
Histology 
Following euthanasia, some of the subdermal explants were removed for fluorescent 
imaging and others were embedded in OCT (Sakura Finetek, Torrance, CA) and frozen 
on dry ice. The frozen tissue was later sectioned and stained following the standard 
Hematoxylin and Eosin (H&E) staining procedure.  The other samples were cover-
slipped with DAPI mounting media (Molecular Probes, Carlsbad, CA) to fluorescently 
image the implanted cells.  
RNA Isolation and Gene Analysis 
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen, 
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100 
Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA). 
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit 
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000 
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR 
Green PCR kit (Qiagen,Valencia, CA), which allows real-time quantity detection of PCR 
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products. Target-specific primers were synthesized by Integrated DNA Technologies Inc. 
(Coralville, IA). Minus RT and minus cDNA samples were included in each set of 
samples. Each sample was normalized to the expression of ß-2 microglobulin (2-MG) as 
a housekeeping gene and compared to control samples (elastin in collagen gel only) using 
the 2
-ΔΔC
T
   
method. 
Calcium and Desmosine Analysis 
The capsule was removed from the day seven explanted samples which were then frozen 
at -80°C and lyophilized.  The dried samples (~10-15 mg) were hydrolyzed in 6 N HCl in 
a boiling water bath.  The hydrochloric acid was evaporated using a continuous stream of 
nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was measured using 
atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer, Norwalk, CT). The 
same hydrolysates were analyzed for desmosine content using radioimmunoassay [127]. 
Statistical Analysis 
Data are reported as means ± SEM. Student‟s t-test was used to determine differences 
between groups. Data are termed statistically significant when p<0.05. 
Results 
Unprocessed tissue samples were analyzed microscopically for the presence of OCs. 
Histological analysis of the unprocessed tissue confirmed the presence of the 
fluorescently labeled OCs (red) at days one and three (Figure 25 A&B respectively). 
H&E staining showed the presence of OCs at day three in the sectioned tissue samples 
(Figure 25 C&D). The presence of OCs could not be confirmed at day seven by 
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histological analysis.  It is not clear what happened to the cells between days three and 
seven, it is possible that they did not survive.  
 
Figure 25. Fluorescently labeled OCs (red) were present in the subdermal implant at days 
one (A) and three (B). H&E staining also shows the presence of OCs (denoted by arrows) 
at day three (C&D). 
The subdermal implants were also examined for gene expression of Cathepsin K, an OC 
specific protease, to further examine why OCs were not visible by histological analysis at 
day seven.  Explants from days three and seven were analyzed for cathepsin K and the 
presence of OCs could only be confirmed in day three explants by an 2.5 fold over-
expression of Cathepsin K (Figure 26). Gene analysis further confirmed histological data 
as no overexpression of Cathepsin K was observed at day seven clearly showing 
functional osteoclast cells were absent at the site.  
A B 
C D 
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Figure 26. Cathepsin K over-expression at day three verifying the presence of OCs (n=3). 
Interestingly, calcium analysis of day seven samples revealed a 56% lower elastin 
calcification in the presence of OCs (Figure 27). Collagen gel with incorporated OCs did 
not calcify.  
 
Figure 27. OCs limit the progression of elastin calcification (n=3). 
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Thus, OCs were effective at limiting the progression of elastin calcification. Next we 
wanted to verify that elastin was not degraded by the OCs.  Elastin integrity was 
examined by desmosine analysis. Desmosine analysis is frequently used to study elastin 
integrity [127]. Desmosine analyses showed no alteration in desmosine levels suggesting 
that OCs did not degrade elastin while limiting the progression of elastin calcification 
(Figure 28).  
 
Figure 28. Elastin was not degraded by OCs during implantation (n=3). 
Discussion 
Our in vitro studies showed that OCs have the ability to resorb calcified elastin, but here 
we examined if they would be able to limit the progression of elastin calcification in vivo. 
Our research group has used this accelerated calcification model previously to investigate 
the mechanisms of elastin calcification and have shown that calcium deposits are 
exclusively related with the elastin fibers [128]. We have also shown that this model 
shares many similarities with bone formation, including the presence of osteoblastic cells 
0
1000
2000
3000
4000
5000
6000
7000
Day 7 EL Only Day 7 OC + EL
p
m
 D
e
s
/m
g
 p
ro
te
in
79 
 
[26]. To the best of our knowledge, this is the first research attempt to use cell therapy for 
limitation of elastin calcification. Since OCs are the only cells capable of resorbing cells 
[129], this approach seems reasonable.  
Calcium analysis of the implants after seven days confirmed our hypothesis that OCs 
would limit the progression of elastin calcification. OCs limited elastin calcification by 
56%. We also examined the integrity of elastin after implantation with OCs to verify no 
degradation of elastin by OCs. Elastin integrity was analyzed by desmosine analysis 
[127] and showed no elastin degradation by OCs.  
We also wanted to confirm the presence of OCs during implantation. The OCs could be 
identified in elastin implants after three days via fluorescence microscopy, histology and 
PCR indicating that live, functional OCs were present. The presence of OCs could not be 
confirmed at day seven indicating a limited life span of OCs after implantation [130]. The 
data suggests that early presence of OCs up to 3 days prevented or delayed initial 
calcification of elastin. Although cells were absent after few days (either died or cleared 
from the area) they were clearly functional in first few days and did limit progression of 
elastin calcification. It may be possible that by day seven remodeling response ensues 
with fibroblast migration and collagen deposition and delivered OCs are removed further 
away from the elastin implant.  
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Chapter Seven 
Evaluation of Site-Specific Delivery of Osteoclasts to Reverse Elastin Calcification in 
vivo 
Introduction 
Thus far we have demonstrated that BMPCs can be differentiated into OCs using vitamin 
D3 with retinoic acid media supplementation. We have also shown that these mature OCs 
have the ability to demineralize calcified elastin in vitro as well as limit the progression 
of elastin calcification in vivo [131]. In a clinical setting elastin would already be 
calcified before treatment would be applied. The reversal of elastin calcification is more 
clinically relevant. Therefore, we attempted to reverse elastin calcification by a site-
specific delivery of OCs.  
Our approach to reverse elastin calcification was a three step effort. All studies began 
with purified elastin being subdermally implanted and allowed to calcify for seven days 
then at day seven a cell therapy treatment was delivered to the site of calcification. First, 
we injected a cell suspension directly into the implant site. Our next effort at treatment 
was reopening the subdermal pocket and implanting a collagen gel with encapsulated 
cells next to the implant. Finally, we reopened the subdermal pocket and implanted 
collagen/alginate beads with cells encapsulated as an attempt to reverse elastin 
calcification. 
Materials and Methods 
Osteoclasts were isolated and differentiated with Vitamin D3 as previously described. For 
elastin calcification studies, porcine aortic elastin was purified and subdermally 
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implanted the same as described in chapter one. The elastin was allowed to calcify for 
seven days before cell therapy treatment. 
Cell Therapy Treatment: 
Cell Injection 
The morning of surgery, mature OCs, BMPCs and rat skin fibroblasts were suspended in 
sterile PBS (1x10
5
 cells/0.5 mL) and sterilely transferred to the surgery suite for 
injections.  Control group includes saline injections (0.5mL/injection). For injections, the 
animals from the previous procedure were held by an assistant while the injections were 
delivered directly to the implant site. The animals were humanely euthanized using CO2 
asphyxiation seven days following application of the treatment. 
Osteoclast Labeling and Collagen Gel Encapsulation 
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE 
(Molecular Probes, Carlsbad, CA). Once labeled, the cells were added to a collagen 
solution previously prepared with eight parts PureCol® (Advanced BioMatrix, San 
Diego, CA), one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium 
Hydroxide (NaOH) in a 50 mL centrifuge tube on ice.  The mixture was vortexed 
vigorously and pH adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl).  The 
cell/collagen mixture was taken up into 1 ml syringes (with tips removed for easier 
implantation) with a cell concentration of 5x10
5
cells/gel and allowed to solidify sterilely 
at 37°C for ~30 minutes. Control groups include collagen only. Once solid, the collagen 
gels with encapsulated DDAO-labeled OCs were sterilely transferred to the surgery suite 
for implantation. 
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The animals from the previous surgery were placed under general anesthesia (2% 
isoflurane) then two incisions were made on the back above the shoulder blades (left and 
right side) followed by the formation of subdermal pockets by blunt dissection to expose 
the previously implanted elastin. Once the previous implant was located, the gels were 
placed next to the elastin implant and the site was closed staples. The animals were 
humanely euthanized using CO2 asphyxiation seven days following application of the 
treatment. 
Collagen/Alginate Bead Preparation 
Beads were prepared by mixing 0.1% w/v sodium alginate (Sigma, St. Louis, MO ) with 
0.1% w/v bovine tendon collagen (EPC,). This mixture was taken up into a syringe and 
placed into a syringe pump (Medfusion Injector, Medex Inc, Yellowknife, NT). The 
solution was then pushed through a 21G needle and dropped into a gently stirring       2% 
w/v calcium chloride (Sigma, St. Louis, MO). Once the mixture was completely 
dispensed, the beads were allowed to stir for one hour to ensure complete crosslinking 
and were then washed three times in DI water.  
Cell Encapsulation in Collagen/Alginate Beads and Viability 
Rat skin fibroblasts were fluorescently labeled with CellTrace™ Far Red DDAO-SE 
(Molecular Probes, Carlsbad, CA) then centrifuged and the cell pellet was added to the 
alginate/collagen mixture then the beads were prepared the same as described above but 
the entire process was performed steriley. After the washing step, the beads with cells 
encapsulated were placed into well plates and cultured for seven days in DMEM with 
10% FBS and 1% Ab/Am. At day seven, media was removed from the cultures and MTS 
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(Promega, Madison, WI) Cell Viability assay was run on the media  then beads were 
removed from the culture dish and picogreen DNA assay (Invitrogen, Carlsbad, CA) was 
performed on cells attached to the culture dish to determine if there was any cell 
proliferation from the beads. 
Osteoclast Labeling and Collagen/Alginate Bead Encapsulation 
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE 
(Molecular Probes, Carlsbad, CA). OCs were encapsulated into the collagen/alginate 
beads the same as described above and transferred to the surgical suite for implantation. 
The animals from the previous surgery were placed under general anesthesia (2% 
isoflurane) then two incisions were made on the back above the shoulder blades (left and 
right side) followed by the formation of subdermal pockets by blunt dissection to expose 
the previously implanted elastin. Once the previous implant was located, the beads were 
placed next to the elastin implant and the site was closed staples. The animals were 
humanely euthanized using CO2 asphyxiation seven days following application of the 
treatment. 
Calcium and Desmosine Analysis 
The capsule was removed from the explanted samples which were then frozen at -80°C 
and lyophilized.  The dried samples (~10-15 mg) were hydrolyzed in 6 N HCl in a 
boiling water bath.  The hydrochloric acid was evaporated using a continuous stream of 
nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was measured using 
atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer, Norwalk, CT). The 
same hydrolysates were analyzed for desmosine content using radioimmunoassay [127]. 
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RNA Isolation and Gene Analysis 
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen, 
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100 
Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA). 
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit 
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000 
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR 
Green PCR kit (Qiagen,Valencia, CA), which allows real-time quantity detection of PCR 
products. Target-specific primers were synthesized by Integrated DNA Technologies Inc. 
(Coralville, IA). Minus RT and minus cDNA samples were included in each set of 
samples. Each sample was normalized to the expression of ß-2 microglobulin (2-MG) as 
a housekeeping gene and compared to control samples (elastin only) using the 2
-ΔΔC
T
   
method. 
 
Results 
Seven days after initial delivery of OCs, elastin was explanted and amount of calcium 
deposited was assayed with atomic absorption spectrophotometry. Calcium analysis 
revealed no significant reduction in calcification of elastin in the presence of any cell type 
injected (Figure 29). Cellular injections proved ineffective for reversal of elastin 
calcification.   
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Figure 29.  Cells injected at the site of elastin calcification were not effective in reducing 
calcification (n=4). 
 
This is possibly because the cells did not remain at the implant site for enough time to 
demineralize the calcified elastin.  Gene analysis showed that Cathepsin K levels were 
two fold higher in all groups including fibroblast group as compared to elastin implant 
control (Figure 30). Clearly, just delivering cells to the site was enough to increase Cat-K 
expression. At seven days, early markers of bone-specific gene, Cbfa-1, remained 
unchanged while alkaline phosphatase, which is expressed during calcification process 
was significantly higher in the OC injection group.  ALP levels encompass more than just 
bone; it refers to the general production of phosphatase.  OCs use phosphatase in the 
process of demineralization and this could be the cause for increased ALP gene 
expression in OC group. 
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Figure 30. Gene analysis of the implants show that cell injections had no effect to reduce 
bone-specific genes (n=4).  
As injections of cells suspended in saline were ineffective in reversing elastin 
calcification probably due to the difficulty of staying in place at the implant site, we then 
decided that some sort of gel delivery system was needed to deliver the cells. Thus, we 
used collagen gels to deliver the cells to the site of calcification. Again, calcium analysis 
of elastin in the collagen gel treatment showed no reduction in elastin calcification in the 
presence of OCs (Figure 31).  
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Figure 31. OCs delivered by collagen gel were ineffective for reversal of elastin 
calcification (n=4). 
Gene analysis showed slightly reduced Cathepsin K levels in the OC group as compared 
to the day fourteen control.  Cbfa-1 gene was over-expressed in the OC group but ALP 
levels were reduced.  
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Figure 32. Gene analysis results vary but the variance was not enough to affect 
calcification. 
Our final attempt to reverse elastin calcification using cell therapy was with 
collagen/alginate beads. In vitro studies were performed first to optimize bead 
preparation and cell encapsulation. Beads were made with varying ratios of collagen and 
alginate and the beads averaged 0.2 cm in size. The beads with equal parts collagen and 
alginate (1:1) were not homogenous in size (Figure 33).  
 
Figure 33. Beads made of varying collagen/alginate concentrations. 
0
0.5
1
1.5
2
2.5
Collagen OC 
R
e
la
ti
ve
 G
e
n
e
 E
xp
re
ss
io
n
Cat K
Cbfa-1
ALP
90 
 
The beads made with 7:3 collagen/alginate were weak and mushy. Increasing 
concentrations of alginate improved stiffness and handling properties of the beads. The 
beads with 3:7 collagen/alginate mixtures showed better handling properties and 
therefore they were used for further studies.  
Cell encapsulation was successful and fluorescently labeled cells were observed within 
the collagen/alginate beads (Figure 34).  
 
Figure 34. Cells (red) were successfully encapsulated into collagen/alginate beads. 
The cells remained viable during encapsulation as confirmed by the MTS cell viability 
assay (Figure 35). While the cells were viable within the bead, picogreen DNA assay 
showed that they did not migrate from thee bead and attach to the culture dish (Figure 
36).  
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Figure 35. Cells encapsulated within collagen/alginate beads are viable and metabolically 
active (n=6). 
 
Figure 36. Encapsulated cells did not proliferate from the beads and attach to the culture 
dish (n=6). 
In vivo analysis of the beads as a delivery vehicle for OCs to reverse elastin calcification 
showed that the collagen/alginate beads kept the cells localized to one specific area 
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(Figure 37). Prior to euthanasia the animals were imaged using Lumazone imaging 
technology to visualize the position of the fluorescently labeled cells.  
 
Figure 37. Imaging of the fluorescently labeled OCs seven days after implantation 
showed that the collagen/alginate beads kept the cells localized during implantation. 
Calcium analysis of the implants did not reveal any difference in calcification in the 
presence of the beads containing OCs (Figure 38).  
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Figure 38. Delivery of OCs by collagen/alginate beads was not effective for reversal of 
elastin calcification (n=4). 
Gene analysis of the implants showed higher expression of Cathepsin K confirming that 
the collagen/alginate beads kept OCs at the implant site while OCs injected as a 
suspension in saline was not effective at keeping cells at the implant site (Figure 39). The 
bone protein expression found was intriguing. When OCs were injected in saline bone 
related genes were significantly over-expressed. Both Cbfa-1 and ALP levels were two 
fold that of the control, but in the group where the OCs were delivered in the beads, the 
levels remained unchanged as compared to the elastin only control. 
 
Figure 39. Gene analysis of the implants confirm that collagen/alginate beads kept OCs at 
the implant site (n=4). 
Discussion 
It has been very well documented that vascular calcification is very similar to that of 
bone mineralization (Jeziorska, 2001; Bobryshev, 1995; Bostrom, 1995). The accelerated 
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calcification model used for this study has been previously used by our research group to 
investigate fundamental mechanisms of elastin calcification [128]. Our group has also 
shown that the elastin calcification observed in this model shares many similarities with 
bone formation, including the presence of osteoblastic cells that are positive for Cbfa-1 
surrounding the calcified elastin [26]. The focus of this aim was to use OCs, the only 
bone resorbing cells [129], to reverse elastin calcification. To our knowledge this was the 
first attempt to use OCs as a cell therapy treatment to reverse elastin calcification. 
Cell therapy is a treatment that has been used for numerous other diseases. More recently 
cell therapy has been proven as a great treatment in the cardiovascular field. Stem cell use 
has also shown great potential in treating hearts damaged by myocardial infarction [120]. 
Transplantation of autologous CD31+ and CD34+ cells induced neovascularization and 
improved ventricular function after myocardial infarction in pig and rat models (Melo, 
2004). Endothelial progenitor cells isolated from the bone marrow have also been used to 
achieve cell-based neovascularization in damaged myocardium (Melo, 2004). The recent 
findings in literature using bone marrow derived stem cells to treat cardiovascular 
diseases supports our hypothesis to use bone marrow derived OCs to treat vascular 
elastin-specific calcification.  
Our attempts to reverse elastin calcification through cell therapy using OCs  did not show 
results that we had hoped. When cells were suspended in saline, the cells did not remain 
at the site of calcification and were ineffective at reversing calcification.  We tried to 
deliver the cells using a delivery vehicle as opposed injecting them in a suspension. OCs 
were incorporated into a collagen gel and delivered to the site of calcification. Previously 
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we have shown collagen gels to be a great delivery vehicle for OCs [131]. However the 
collagen gel didn‟t keep the cells localized long enough for the cells to have an effect on 
calcification. Our last attempt using a delivery vehicle was with the use of 
collagen/alginate beads. We showed that we could encapsulate the cells into the beads 
and the cells remained viable during encapsulation [132]. The beads were very effective 
at keeping the cells localized to a specific area but the cells did not proliferate and 
migrate out from the beads to reverse elastin calcification. We used collagen/alginate 
beads with the intention of alginate degraded slower than collagen alone to ensure the 
cells would be kept in place and the delivery vehicle degrade slowly for the cells to 
remain at the implant site longer and be able to reverse calcification.  The 
collagen/alginate beads did degrade slower than the collagen gel alone but unfortunately 
too slowly. The beads could still be found at the implant site at the time of euthanasia. 
Literature has shown the use of alginate to long-term cell entrapment and immobilization 
as opposed to a short-term delivery vehicle followed by in vivo degradation [84, 132]. 
The bone protein data was intriguing. When osteoclast cells were delivered in saline 
because of their presence bone protein levels were also higher. It is possible that body is 
trying to regulate mineral formation and resorbtion to a certain degree. In bone, OCs 
regulate behavior of osteoblasts and vice versa. It is thus possible that presence of OCs 
allowed increased bone cell type phenotype from nearby cells. When OCs were 
encapsulated in beads, they remained entrapped and did not cause this response in the 
nearby cells. Overall, it is clear that it is difficult to tilt the balance to osteoclastogenesis 
from osteoblastogenesis when the calcification has already progressed to a certain degree. 
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It is also very difficult to deliver large cells like OCs to the site of calcification and keep 
them functional as our attempts to modify delivery methods failed to result in any 
success.  Further work in this area needs to focus on optimization of degradation of 
delivery vehicle before attempting to use it for cell therapy to reverse calcification. It is 
also possible that one can stop initiation of calcification of elastin as it is regulated 
process but progression of calcification may occur by physical mineral deposition 
(without regulation from cells) and delivery of cells may not prove successful. 
  
97 
 
 
 
References 
 
1. Simpson, C.L., et al., Toward cell therapy for vascular calcification: osteoclast-
mediated demineralization of calcified elastin. Cardiovasc Pathol, 2007. 16(1): p. 
29-37. 
2. Starcher, B.C., Determination of the elastin content of tissues by measuring 
desmosine and isodesmosine. Anal Biochem, 1977. 79(1-2): p. 11-5. 
3. Bailey, M.T., et al., Role of elastin in pathologic calcification of xenograft heart 
valves. J Biomed Mater Res A, 2003. 66(1): p. 93-102. 
4. Lee, J.S., et al., Elastin calcification in the rat subdermal model is accompanied 
by up-regulation of degradative and osteogenic cellular responses. Am J Pathol, 
2006. 168(2): p. 490-8. 
5. Teitelbaum, S.L., Bone resorption by osteoclasts. Science, 2000. 289(5484): p. 
1504-8. 
6. Aranguren, X.L., C.M. Verfaillie, and A. Luttun, Emerging hurdles in stem cell 
therapy for peripheral vascular disease. J Mol Med, 2009. 87(1): p. 3-16. 
7. Yagar, H., F. Ertan, and B. Balkan, Comparison of some properties of free and 
immobilized alpha-amylase by Aspergillus sclerotiorum in calcium alginate gel 
beads. Prep Biochem Biotechnol, 2008. 38(1): p. 13-23. 
98 
 
8. Collin-Osdoby, P., Regulation of vascular calcification by osteoclast regulatory 
factors RANKL and osteoprotegerin. Circ Res, 2004. 95(11): p. 1046-57. 
 
 
  
99 
 
 
 
Chapter Eight 
Evaluation of RANKL as a Recruiter of Native Osteoclasts to Demineralize 
Calcified Elastin in vivo 
Introduction 
In previous chapters we established that Vitamin D3 with retinoic acid media 
supplementation can differentiate BMPCs into OCs and the differentiated cells 
significantly demineralize calcified elastin in vitro.  Mature OCs were also able to limit 
the progression of elastin calcification in vivo. Previously we have attempted to deliver 
allogenic OCs to the site of calcification and it was proven ineffective at reversing 
calcification.  For this aim we tested whether recruitment of native OCs to the site of 
calcification (by RANKL delivery) would attenuate calcification process.  In a clinical 
setting, it would require less surgical manipulation to recruit native cells than 
transplanting cells differentiated in vitro. We hypothesized that injections of RANKL to 
the site of calcification can differentiate native monocyte/macrophage cells into mature 
OCs. These newly recruited cells then would be able to demineralize calcified elastin 
without causing any elastin degradation. RANKL is the key factor for OC formation in 
bone. Since vascular calcification resembles bone we wanted to examine if RANKL 
could be effective to recruit native OCs to the site of elastin calcification and reverse the 
calcification process.  We also examined the effect of osteoprotegrin (OPG) on OC 
recruitment.  As discussed in the literature review, mature OCs are formed by RANKL 
binding to RANK on the pre-osteoclasts.  OPG can also bind to RANK and inhibit the 
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binding of RANKL; therefore, inhibiting the formation of mature OCs. Dosages of 
RANKL and OPG injections for this study were determined by previous findings of our 
collaborators, who examined the effect of RANKL on osteoclastogenesis in bone [133]. 
To examine our hypothesis we used the subdermal calcification model of purified porcine 
elastin. Once elastin calcification occurred (seven days) RANKL was delivered to the site 
of calcification twice daily for seven days.  We also examined the effect of OPG, which 
functions as an antagonist of the effects of RANKL.  Tissue explants were examined for 
calcium levels, elastin degradation by desmosine content, RANKL levels, and gene 
expression of Cathepsin K, an OC specific gene and Cbfa-1 and ALP, bone specific 
genes. 
Materials and Methods 
RANKL/OPG Injections 
Porcine aortic elastin was purified the same as before and implanted following the same 
methods used in chapter one. The elastin was allowed to calcify for seven days.  At day 
seven injections began for recruitment.  RANKL and OPG were delivered into each 
implant twice daily at doses of 0.4 mg/kg and 0.5 mg/kg, respectively (n=4).  Control 
injections of saline were delivered twice daily at a volume of 0.1 ml/implant (n=4).   The 
animals were humanely euthanized using CO2 asphyxiation seven days later at day 
fourteen. 
Calcium and Desmosine Analysis 
The tissue capsule was removed from the explanted elastin samples. The elastin implant 
was then frozen at -80°C and lyophilized.  The dried samples (~10-15 mg) were 
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hydrolyzed in 6 N HCl in a boiling water bath.  The hydrochloric acid was evaporated 
using a continuous stream of nitrogen gas then reconstituted in 0.01 N HCl. Calcium 
content was measured using atomic absorption spectrophotometry (Aanalyst 200, Perkin-
Elmer, Norwalk, CT). The same hydrolysates were analyzed for desmosine content using 
radioimmunoassay [127]. 
RANKL ELISA 
Explanted tissue was pulverized and homogenized in RIPA extraction buffer (50nM Tris, 
150 mM NaCl, 1% Triton X-100, 1% Sodium Deoxycholate, 0.1% SDS, pH 7.4) and 
protein concentrations were determined using BCA assay kit (Pierce, Rockford, IL).  
Protein samples were then analyzed for RANKL levels using an ELISA kit (R&D 
Systems, Minneapolis, MN) following manufacturer‟s instructions. 
RNA Isolation and Gene Analysis 
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen, 
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100 
Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA). 
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit 
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000 
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR 
Green PCR kit (Qiagen,Valencia, CA), which allowed real-time quantity detection of 
PCR products. Target-specific primers were synthesized by Integrated DNA 
Technologies Inc. (Coralville, IA). Minus RT and minus cDNA samples were included in 
each set of samples. Each sample was normalized to the expression of ß-2 microglobulin 
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(2-MG) as a housekeeping gene and compared to control samples (elastin only) using 
the     2
-ΔΔC
T
   
method. 
Statistical Analysis 
Data are reported as means ± SEM. Student‟s t-test was used to determine differences 
between groups. Data are termed statistically significant when p<0.05. 
Results 
Calcium analysis of elastin explants showed that RANKL injections were not effective at 
reversing elastin calcification.  Calcium levels of the RANKL group were not 
significantly lower than the saline control group (Figure 40).  OPG injections also had no 
effect on elastin calcification. 
 
Figure 40. RANKL and OPG injections had no effect on elastin calcification (n=4). 
Desmosine levels were not decreased due to RANKL or OPG injections indicating no 
degradation of elastin (Figure 41). 
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Figure 41. Elastin is not degraded by injections of RANKL and OPG as shown by 
desmosine levels (n=4).  
RANKL protein levels were analyzed to better understand the results of the calcium 
analysis.  We wanted to determine if RANKL levels remained elevated during the 
injection period.  ELISA results showed the RANKL levels of the control group were not 
significantly lower than that of the RANKL injection group (Figure 42) indicating that 
the injections did not maintain active RANKL levels at the site of implant to be effective 
at demineralization of elastin implant. On the other hand locally delivered OPG 
significantly reduced RANKL levels. 
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Figure 42. RANKL levels of the control are not significantly lower than that of the 
RANKL injection group (n=4). 
Our group has previously shown that subdermal elastin calcification expresses numerous 
bone genes and proteins [26]. We wanted to examine if RANKL and OPG injections had 
any effect on the gene level that may not have been expressed by calcification analysis.  
We also examined Cathepsin K gene expression to determine if there was any presence of 
osteoclasts at the calcification site.  RANKL injections decreased the expression of bone 
proteins Cbfa-1 and ALP but had no effect on reversing calcification.  Cathepsin K levels 
were also down regulated by RANKL injections indicating fewer osteoclasts as compared 
to the elastin only control group (Figure 43). OPG injections did not exhibit decreased 
Cathepsin K levels compared to the control.  Even though Cbfa-1 gene expression was 
not affected by OPG injections ALP was down regulated by OPG injections as compared 
to control saline injections. 
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Figure 43. RANKL injections down regulate Cathepsin K and bone markers compared to 
saline injection controls while OPG injections only had an effect on ALP (n=4). 
Discussion 
Over the last decade many studies have confirmed that vascular calcification is an active 
regulated process similar to that of physiologic bone mineralization and associated with 
the presence of bone growth factors and matrix proteins (Shoi, 2000; Wallin, 2001). The 
overall aim of this study was based on the similarities between vascular calcification and 
bone.  In previous chapters we have shown that BMPCs differentiated with Vitamin D3 
and Retinoic acid into mature OCs can demineralize calcified elastin in vitro. They also 
have the ability to limit the progression of elastin calcification in vivo if delivered before 
the initiation of calcification [131]. In an attempt to mimic a clinical setting, where 
patients coming to the clinic would already have calcific disease, we adapted our model 
and allowed for elastin to calcify to moderate levels before the delivery of allogenic OCs 
to reverse calcification.  Our previous approaches of local delivery of osteoclasts were 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
RANKL OPG
R
e
la
ti
v
e
 G
e
n
e
 E
x
p
re
s
s
io
n
Cat K
CBFA-1
ALP
106 
 
unsuccessful so we turned our focus toward recruitment of native cells by RANKL 
delivery. We thought that delivery small protein molecule like RANKL would be easier 
than delivering mature osteoclasts. 
In bone, homeostasis is maintained through the RANK/RANKL/OPG system (Schoppet, 
2004; Li, 2000; Boyce, 2005).  RANKL (previously called OPGL) was first discovered as 
a replacement for stromal cells and vitamin D3 in osteoclast cell cultures in 1998 by 
Lacey and associates (Lacey, 1998; Kong, 1999; Kong, 1999).  RANKL binds to RANK, 
which is expressed on pre-osteoclasts.  The binding is essential for all aspects of 
osteoclast function such as differentiation, maturation, fusion, survival and activity. OPG 
is a soluble factor produced by some cells that strongly inhibits osteoclast formation in 
vitro and in vivo.  OPG prevents binding of RANKL to its receptor RANK [77].   
Our findings showed that both RANKL and OPG had no effect on reversing elastin 
calcification that was already progressed to a moderate level.  Many factors may be 
responsible for this ineffectiveness. Protein analysis by ELISA also showed that RANKL 
levels were not maintained at an active level to affect calcification.  Thus, injections of 
RANKL daily at the site were not enough to keep local RANKL levels high enough to 
cause cell recruitment. It is possible that RANKL was delivered in solution and was 
cleared from the area within few minutes to hours by circulatory system. More sustained 
release through delivery systems such as osmotic pumps may have been more effective.  
Gene analysis for bone markers showed down regulation (Cbfa-1 and ALP) in RANKL 
group clearly showing some effect on osteogenesis; however, it was not enough to have 
an effect on progression of calcification. It is possible that once moderate calcification 
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takes place, continuous deposition of mineral occurs due to physical factors and not by 
cellular pathways.  Injections of OPG did significantly reduce levels of RANKL as 
confirmed by ELISA clearly showing that OPG delivery did affect RANKL. However, 
Cathepsin K (for osteoclast) and Cbfa-1 (for osteoblast) genes were unaffected compared 
to the control (saline injections). Only the ALP gene was down-regulated in OPG groups 
but it also did not inhibit the progression of calcification.   
  
108 
 
 
References 
1. Yuan, Y., The differential effects of two critical osteoclastogenesis stimulating 
factors on bone biomechanics. 2007: Clemson University. 
2. Starcher, B.C., Determination of the elastin content of tissues by measuring 
desmosine and isodesmosine. Anal Biochem, 1977. 79(1-2): p. 11-5. 
3. Lee, J.S., et al., Elastin calcification in the rat subdermal model is accompanied 
by up-regulation of degradative and osteogenic cellular responses. Am J Pathol, 
2006. 168(2): p. 490-8. 
4. Simpson, C.L., et al., Toward cell therapy for vascular calcification: osteoclast-
mediated demineralization of calcified elastin. Cardiovasc Pathol, 2007. 16(1): p. 
29-37. 
5. Schoppet, M., et al., Localization of osteoprotegerin, tumor necrosis factor-
related apoptosis-inducing ligand, and receptor activator of nuclear factor-
kappaB ligand in Monckeberg's sclerosis and atherosclerosis. J Clin Endocrinol 
Metab, 2004. 89(8): p. 4104-12. 
 
 
  
109 
 
Chapter Nine 
Evaluation of osteoclasts to reverse arterial elastin-specific calcification in an 
abdominal aortic injury model 
Introduction 
Arterial calcification resembles intra membranous bone formation with active 
osteoblastic remodeling [4] [5]. Our hypothesis is that a site-specific delivery of 
osteoclasts, bone resorbing cells, would tilt the balance to mineral resorption rather than 
mineral deposition thus limiting vascular calcification. In previous chapters we have 
shown that OCs can resorb calcium from calcified elastin in vitro and limit the 
progression of  calcification of pure elastin in vivo in a rat subdermal implantation model 
[131].  However, attempts to reverse elastin calcification in subdermal model either by 
delivering allogenic mature OCs or recruitment of native OCs by RANKL delivery were 
unsuccessful. 
All of this previous work was performed on purified porcine elastin to simulate vascular 
medial calcification. For this study we wanted to study if OCs can be delivered to native 
calcified arteries by periadeventitial route. We used an abdominal aortic injury model 
which has been shown to induce medial elastin-specific calcification in rats [134].  It was 
hypothesized that OCs will enter the medial layer of arteries where calcification is found 
in this model and prevent progression of calcification. This is most clinically relevant 
examination of our hypothesis.  Abdominal aorta of rats were periadeventially treated 
with calcium chloride for 15 minutes to create inflammatory conditions which is shown 
to lead to progressive medical calcification. For this study, immediately after calcium 
chloride injury, we placed collagen gel encapsulated with OCs periadentially to the aortic 
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site.  The calcification was allowed to progress for 7 days and then abdominal aortic 
tissue explants were examined qualitatively and quantitatively for calcification, presence 
of OCs, and for elastin integrity. 
Materials and Methods 
Osteoclasts were isolated using the same methods as those described previously. 
Osteoclast Labeling and Collagen Gel Encapsulation 
The morning of surgery mature OCs were labeled using CellTrace™ Far Red DDAO-SE 
(Molecular Probes, Carlsbad, CA). Once labeled, the cells were added to a collagen 
solution previously prepared with eight parts PureCol® (Advanced BioMatrix, San 
Diego, CA), one part 10X Phosphate Buffered Saline (PBS) and one part 0.1 M Sodium 
Hydroxide (NaOH) in a 50 mL centrifuge tube on ice.  The mixture was vortexed 
vigorously and pH adjusted to 6.5-7.0 with 0.5 M Hydrochloric Acid (HCl).  The 
cell/collagen mixture was taken up into 1 ml syringes (with tips removed for easier 
implantation) with a cell concentration of 1x10
5
cells/gel and allowed to solidify sterilely 
at 37°C for ~30 minutes. Once solid, the collagen gels with encapsulated DDAO-labeled 
OCs were sterilely transferred to the surgery suite for implantation. 
Abdominal Aortic Injury Surgery 
Adult male Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN) weighing ~250 
g were placed under general anesthesia (2% isoflurane) then the infrarenal aorta (between 
the renal artery and iliac bifurcation) was exposed and 0.15M CaCl2 soaked sterile cotton 
gauze was applied for 15 minutes to induce calcification.  The gauze was then removed 
and abdominal cavity was rinsed three times with warm sterile saline.  The experimental 
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group (n=5) received the application of the collagen gel with the encapsulated DDAO-
labeled OCs to the previously treated aorta while the control group (n=5) received none.  
The abdominal cavity was closed followed by subcutaneous sutures and staples.  The 
animals were humanely euthanized at day seven and each injured aorta was retrieved and 
processed for histological analysis, calcium and desmosine content and gene expression. 
Histology 
Following euthanasia, the aortic tissue was embedded in OCT (Sakura Finetek, Torrance, 
CA) and frozen on dry ice. The frozen tissue was later sectioned and stained for calcium 
deposits following the Dahl‟s Alizarin Red procedure.  Sectioned and unstained tissue 
was cover-slipped with DAPI mounting media (Molecular Probes, Carlsbad, CA) to 
fluorescently image the implanted cells. 
Calcium and Desmosine Analysis  
The capsule was removed from the explanted samples which were then frozen at -80°C 
and lyophilized.  The dried samples (~10-15 mg) were hydrolyzed in 6 N HCl in a 
boiling water bath.  The hydrochloric acid was evaporated using a continuous stream of 
nitrogen gas then reconstituted in 0.01 N HCl. Calcium content was measured using 
atomic absorption spectrophotometry (Aanalyst 200, Perkin-Elmer, Norwalk, CT). The 
same hydrolysates were analyzed for desmosine content using radioimmunoassay [127]. 
 
RNA Extraction and Gene Analysis 
Total RNA was isolated from tissue explants using the RNeasy Fibrous Kit (Qiagen, 
Valencia, CA). Quality and quantity of RNA were evaluated on an Agilent 2100 
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Bioanalyzer using the RNA 6000 Nano kit (Agilent Technologies Inc., Foster City, CA). 
Five hundred nanograms of total RNA was then reverse transcribed using RetroScript Kit 
(Ambion, Austin, TX). The cDNA sample was further amplified using a Rotorgene 3000 
thermal cycler (Corbett Research, Mortlake, NSW, Australia) and QuantiTect SYBR 
Green PCR kit (Qiagen,Valencia, CA), which allows real-time quantity detection of PCR 
products. Target-specific primers were synthesized by Integrated DNA Technologies Inc. 
(Coralville, IA). Minus RT and minus cDNA samples were included in each set of 
samples. Each sample was normalized to the expression of GAPDH as a housekeeping 
gene and compared to control samples (CaCl2 only) using the 2
-ΔΔC
T
   
method. 
Results 
Frozen sections were stained for calcium by alizarin red. The control group where only 
collagen gel was used showed strong red staining for calcification in the media of the 
artery while OCs group showed little to no staining for calcium. (Figure 44) To test 
whether osteoclasts that were delivered stayed in place we used fluorescent imaging. OCs 
were tagged with DDAO that stains them red. In OCs group we found more red staining 
for cells as compared to control in the adventitia of the aorta. When DAPI counter stain 
was used for the same section the red staining corresponded with clumped multinuclear 
cells. This data suggested that delivered OCs survived and were present at the site at the 
time of explanation.  However, the cells were only seen in the adventitial region of the 
aorta and not in the media. Calcification was mainly observed in the medial region of the 
aorta. It seems that OCs did not migrate through to the medial layer where the 
calcification was located.  
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Figure 44. Histological analysis shows the calcification (red of Alizarin Red staining) is 
isolated to the medial layer and although OCs were successfully delivered, they are only 
in the adventitial layer and did not migrate to the site of calcification. 
We also tested OCs presence by quantitative cathepsin gene activity by RT-PCR (known 
marker for OCs). Gene analysis confirmed that that there was four- fold increase in 
Cathepsin K gene expression in OCs group as compared to controls clearly showing that 
OCs were present and were expressing CatK. (Figure 45). 
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Figure 45. Gene analysis confirms the successful delivery of OCs (n=4). 
 
Quantitative calcium analysis (Figure 46) contradicted the histological findings because 
there was no significant reduction in calcification by the delivery of OCs. In this study 
quantitative calcium data showed far lower calcium levels in both groups as compared 
our previously published results [134].   
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Figure 46. Locally delivered OCs did not have an effect on reducing calcification (n=5). 
We also tested if osteoclast delivery would increase elastin degradation in the arteries as 
OCs are known to secrete ECM degrading enzymes. Desmosine analysis confirmed that 
there was no significant elastin degradation by the delivery of the OCs (Figure 47). 
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Figure 47. Elastin integrity is maintained in the presence of OCs (n=5). 
Discussion 
Medial elastin-specific calcification is observed in many different diseases such as 
Monckenberg‟s sclerosis, ageing, diabetes and end-stage renal failure. Previous work by 
our research group has shown that the application of CaCl2 to the abdominal aorta of a rat 
results in medial elastin-associated calcification [134]. Gene analysis of this previous 
work showed that this model expressed osteogenic genes. Given the similarities between 
vascular calcification and bone, we attempted to reverse medial calcification with a site-
specific delivery of OCs. Native arteries do not express any resemblance to bone but 
during diseased states such as Monckeberg‟s sclerosis, bone matrix proteins are 
expressed [24].  
Attempting to reverse vascular calcification using cell therapy is a novel concept. We 
were able to successfully deliver the OCs to the injured tissue as confirmed by histology 
and gene expression but the cells only migrated to the adventitial layer of the artery 
which was also observed by histological analysis.  Successful delivery of the OCs was 
not effective at demineralizing the medial vascular calcification because calcium analysis 
did not show any reduction of calcification in the presence of OCs.  Also the calcification 
was isolated to the medial layer of the aorta as confirmed by Alizarin Red staining and 
the OCs were only in the adventitial layer and did not penetrate to the medial layer to 
reverse calcification. It is also important to note that our studies did not induce 
calcification to the level of that previously shown by our group. Previous studies were 
able to induce calcification using CaCl2 to ~15ug Ca/mg dry tissue, while our study only 
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calcified to 1.5ug Ca/mg dry tissue. The reason for this lower calcification is unknown. It 
is possible that because we did not find any significant calcification in control group, we 
were unable to show lower calcification in the osteoclast group. Only one of control 
group vessel showed significant calcified area (by alizarin red) while none of the 
osteoclast group showed any alizarin staining. This makes us speculate that study was 
successful but due to insufficient numbers of animals no conclusions could be drawn 
whether calcification was reduced or not. This warrants repetition of the study.  
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Chapter Ten 
Conclusions and Recommendations 
Conclusions 
The basis of this dissertation was the similarities between bone mineralization and 
vascular calcification. We hypothesized that a site-specific delivery of osteoclasts, the 
only bone resorbing cells, would be able to limit and reverse vascular elastin 
calcification. For this we determined the most effective method of media supplementation 
for OC differentiation from BMPCs. These cells were effective at forming resorption pits 
on hydroxyapatite discs and demineralize calcified elastin. Next, OCs were cultured to 
maturity using the chosen method of Vitamin D3 with retinoic acid and were also able to 
form resorption pits on hydroxyapatite discs and demineralize calcified elastin. In vivo 
studies then confirmed that OCs were able to limit the progression of elastin calcification 
using a rat subdermal model for accelerated elastin calcification.  
Using the same model we then attempted to reverse elastin calcification. Elastin was 
allowed to calcify before the cell therapy treatment was applied. Three different delivery 
methods were used for this attempt at cell therapy. First, cells were suspended in saline 
and injected directly into the elastin implant. This approach had no effect on reducing 
calcification probably because the cells did not remain at the implant site. Next, cells 
were encapsulated into a collagen gel for delivery to the implant site. Collagen did not 
serve as the ideal delivery vehicle because it degraded too quickly and did not keep the 
cells at the implant site. Lastly, collagen/alginate beads were used as the delivery vehicle 
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for OCs. The beads did keep the cells localized but did not degrade during the in vivo 
study for the OCs to have an effect on calcification.  
We also attempted to recruit native OCs to the site of calcification using RANKL. 
Injections of RANKL did not effectively recruit native OCs in vivo to reduce 
calcification. 
The second animal model used was a circulatory more clinically relevant model. We 
attempted to create medial vascular calcification and deliver OCs to the injured tissue to 
reverse calcification. OCs were successfully delivered to the vascular tissue but only to 
the adventitial layer and not the medial layer where the calcification was located. Our 
aortic tissue also did not calcify to extent of that observed by previous studies. 
Recommendations 
Many studies have shown the numerous similarities between vascular calcification and 
bone mineralization and several review articles have contemplated OCs being the key to 
reverse vascular calcification. Given the success of our in vitro studies, it seems the in 
vivo studies would have similar results. Reversal of calcification is still possible but two 
factors need to be optimized. The delivery vehicle and the duration of the cell therapy 
treatment should be ideal. 
The delivery vehicle should be optimized first by performing an extensive literature 
review to identify a few possible options for a polymer delivery vehicle. The polymers 
should then undergo an in vivo time-course degradation study. Cells could be 
fluorescently labeled and incorporated into the polymers and degradation could be 
visualized using the same Lumazone imaging technology that was used for this 
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dissertation. Once an ideal polymer is identified, the duration of the cell therapy 
treatment should be optimized. 
In vivo studies involve many different factors that are not present in vitro and OCs may 
need to more time to reverse elastin calcification. A time-course study would be needed 
to determine the ideal duration of the cell therapy treatment to ensure that OCs could 
have a chance to reverse calcification. 
The circulatory model study would need to be repeated to achieve the calcification levels 
observed by others. 
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